StayHome personal page - To The Moon

StayHome

StayHome

No personal profile

744Follow

108Followers

6Topic

0Badge

2023-05-05

Great ariticle, would you like to share it?

@IPO_Focus:J&J spinoff Kenvue IPO prices at $22, valuation surpass $40 billion

2023-05-05

Great ariticle, would you like to share it?

@Tiger_Wealth:25bps Rate Hike in May’s FOMC Meeting: Fed Pause on The Horizon

2023-03-21

[Strong]

@CL_Wong:老虎交易平臺 1）讓我可以對美股、港股、期貨、新加坡股等等股票關注。這裏有“老虎社區”讓我每天可以閱讀熱門帖子，並學習股票交易知識。 2）提供美股、港股、期貨、新加坡股等等的交易平臺，也提供貨幣兌換，簡單又方便。

2023-03-21

[Miser]

@SpicyTrade: Welcome to UBS ( $UBS ) stock analysis Date :March 20, 2023 Please note: All stock analysis posted here is for information and ...UBS ( $UBS ) stock analysisFrom Youtube: https://www.youtube.com/watch?v=9V2Z0KnPsMw

2023-03-17

[Miser]

Microsoft Unveils AI Office Copilot In Fast-Moving Race With Google

2022-12-23

[Miser]

2022-12-22

[Cool]

2022-12-21

[Miser]

2022-12-20

[Cool] [Victory] [Strong]

2022-12-19

[Cool]

2022-12-17

🏆

2022-12-16

[Victory]

2022-12-15

[Cool] ⚽️🤑🇦🇷🇫🇷

2022-12-14

⚽️⚽️⚽️

2022-12-13

[Cool]

2022-12-12

$Apple(AAPL)$ [Observation]

2022-12-11

[Miser]

2022-12-11

$Tesla Motors(TSLA)$ [Observation]

2022-12-10

[Smile]

2022-12-09

$Apple(AAPL)$ [Observation]

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3586303845668227","uuid":"3586303845668227","gmtCreate":1623211951029,"gmtModify":1623218455062,"name":"StayHome","pinyin":"stayhome","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","hatId":"ca_profile_frame_Mpy1eK","hatName":"","vip":1,"status":2,"fanSize":108,"headSize":744,"tweetSize":547,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":6,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.01.24","exceedPercentage":"60.16%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.01.24","exceedPercentage":"80.20%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"60.94%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9947256253,"gmtCreate":1683218141972,"gmtModify":1683218144631,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947256253","repostId":"9947236156","repostType":1,"repost":{"id":9947236156,"gmtCreate":1683171050875,"gmtModify":1683171081491,"author":{"id":"9000000000000621","authorId":"9000000000000621","name":"IPO_Focus","avatar":"https://static.tigerbbs.com/d2bf8c09d82876917f67d8a77f54c449","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"9000000000000621","authorIdStr":"9000000000000621"},"themes":[],"title":"J&J spinoff Kenvue IPO prices at $22, valuation surpass $40 billion","htmlText":"1. <a href=\"https://ttm.financial/S/KVUE\">$Kenvue Inc.(KVUE)$</a> will begin trading on NYSE on Thursday <a href=\"https://ttm.financial/S/JNJ\">$Johnson &amp; Johnson(JNJ)$</a> 's consumer health business, Kenvue, will be officially listed on the New York Stock Exchange on May 4, Eastern Time, under the stock code \"KVUE\" <a href=\"https://ttm.financial/S/KVUE\">$Kenvue Inc.(KVUE)$</a> .Kenvue plans to issue 151.2 million common shares in this IPO, with an issuance range between $20 and $23 per share. Goldman Sachs, JPMorgan Chase, Bank of America, Citigroup, Deutsche Bank, BNP Paribas and other top international investment banks participated in this offering.It is worth mentioning that the actual issue size of Kenvue has been further increased to 172.8 million common shares at an issue price","listText":"1. <a href=\"https://ttm.financial/S/KVUE\">$Kenvue Inc.(KVUE)$</a> will begin trading on NYSE on Thursday <a href=\"https://ttm.financial/S/JNJ\">$Johnson &amp; Johnson(JNJ)$</a> 's consumer health business, Kenvue, will be officially listed on the New York Stock Exchange on May 4, Eastern Time, under the stock code \"KVUE\" <a href=\"https://ttm.financial/S/KVUE\">$Kenvue Inc.(KVUE)$</a> .Kenvue plans to issue 151.2 million common shares in this IPO, with an issuance range between $20 and $23 per share. Goldman Sachs, JPMorgan Chase, Bank of America, Citigroup, Deutsche Bank, BNP Paribas and other top international investment banks participated in this offering.It is worth mentioning that the actual issue size of Kenvue has been further increased to 172.8 million common shares at an issue price","text":"1. $Kenvue Inc.(KVUE)$ will begin trading on NYSE on Thursday $Johnson & Johnson(JNJ)$ 's consumer health business, Kenvue, will be officially listed on the New York Stock Exchange on May 4, Eastern Time, under the stock code \"KVUE\" $Kenvue Inc.(KVUE)$ .Kenvue plans to issue 151.2 million common shares in this IPO, with an issuance range between $20 and $23 per share. Goldman Sachs, JPMorgan Chase, Bank of America, Citigroup, Deutsche Bank, BNP Paribas and other top international investment banks participated in this offering.It is worth mentioning that the actual issue size of Kenvue has been further increased to 172.8 million common shares at an issue price","images":[{"img":"https://static.tigerbbs.com/67766f2b047465bb9040fc9e8c4a8c45","width":"1080","height":"478"},{"img":"https://static.tigerbbs.com/5f4d48fd493702d1ce9a00a8165916c0","width":"1080","height":"411"},{"img":"https://community-static.tradeup.com/news/0699127573c334f36ab8a83764d56050","width":"560","height":"240"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947236156","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":552,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9947256847,"gmtCreate":1683218120289,"gmtModify":1683218124039,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947256847","repostId":"9947269379","repostType":1,"repost":{"id":9947269379,"gmtCreate":1683198790891,"gmtModify":1683198818640,"author":{"id":"4115188532413322","authorId":"4115188532413322","name":"Tiger_Wealth","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4115188532413322","authorIdStr":"4115188532413322"},"themes":[],"title":"25bps Rate Hike in May’s FOMC Meeting: Fed Pause on The Horizon","htmlText":"In a widely anticipated move, the US Federal Reserve raised interest rates for the 10th time in just over a year. The Fed fund rate now stands at a target range of 5%-5.25%, which is the highest it has been since August 2007.Source: Bloomberg&nbsp;During the news conference that followed the meeting, Chairman Jerome Powell confirmed that \"a decision on a pause was not made today.\" This is despite the omission of a sentence stating that “the Committee anticipates that some additional policy firming may be appropriate.\" It appears that the Fed has finally reached the terminal rates it had set out to achieve.&nbsp;S&amp;P 500 &amp; Nasdaq Index, Source: Bloomberg The bond markets initially priced a rate hike in the June Fed meeting. However, the sentiment soon changed into a likely rate pause","listText":"In a widely anticipated move, the US Federal Reserve raised interest rates for the 10th time in just over a year. The Fed fund rate now stands at a target range of 5%-5.25%, which is the highest it has been since August 2007.Source: Bloomberg&nbsp;During the news conference that followed the meeting, Chairman Jerome Powell confirmed that \"a decision on a pause was not made today.\" This is despite the omission of a sentence stating that “the Committee anticipates that some additional policy firming may be appropriate.\" It appears that the Fed has finally reached the terminal rates it had set out to achieve.&nbsp;S&amp;P 500 &amp; Nasdaq Index, Source: Bloomberg The bond markets initially priced a rate hike in the June Fed meeting. However, the sentiment soon changed into a likely rate pause","text":"In a widely anticipated move, the US Federal Reserve raised interest rates for the 10th time in just over a year. The Fed fund rate now stands at a target range of 5%-5.25%, which is the highest it has been since August 2007.Source: Bloomberg During the news conference that followed the meeting, Chairman Jerome Powell confirmed that \"a decision on a pause was not made today.\" This is despite the omission of a sentence stating that “the Committee anticipates that some additional policy firming may be appropriate.\" It appears that the Fed has finally reached the terminal rates it had set out to achieve. S&P 500 & Nasdaq Index, Source: Bloomberg The bond markets initially priced a rate hike in the June Fed meeting. However, the sentiment soon changed into a likely rate pause","images":[{"img":"https://community-static.tradeup.com/news/80116eeef27dd0f8dcbc4361429d763c","width":"752","height":"462"},{"img":"https://community-static.tradeup.com/news/8c180491c8a6d0bbb5ee2b75e1104e29","width":"761","height":"453"},{"img":"https://community-static.tradeup.com/news/e630ae790463ff9fb94d3927639fc388","width":"774","height":"438"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947269379","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":4,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":350,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9943853667,"gmtCreate":1679366622959,"gmtModify":1679366626563,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"[Strong]&nbsp;","listText":"[Strong]&nbsp;","text":"[Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9943853667","repostId":"9943859167","repostType":1,"repost":{"id":9943859167,"gmtCreate":1679365913059,"gmtModify":1679365918384,"author":{"id":"3586994859303940","authorId":"3586994859303940","name":"CL_Wong","avatar":"https://static.tigerbbs.com/a974b1a26fc593e3134cf7e90be9c166","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3586994859303940","authorIdStr":"3586994859303940"},"themes":[],"htmlText":"老虎交易平臺 1）讓我可以對美股、港股、期貨、新加坡股等等股票關注。這裏有“老虎社區”讓我每天可以閱讀熱門帖子，並學習股票交易知識。 2）提供美股、港股、期貨、新加坡股等等的交易平臺，也提供貨幣兌換，簡單又方便。","listText":"老虎交易平臺 1）讓我可以對美股、港股、期貨、新加坡股等等股票關注。這裏有“老虎社區”讓我每天可以閱讀熱門帖子，並學習股票交易知識。 2）提供美股、港股、期貨、新加坡股等等的交易平臺，也提供貨幣兌換，簡單又方便。","text":"老虎交易平臺 1）讓我可以對美股、港股、期貨、新加坡股等等股票關注。這裏有“老虎社區”讓我每天可以閱讀熱門帖子，並學習股票交易知識。 2）提供美股、港股、期貨、新加坡股等等的交易平臺，也提供貨幣兌換，簡單又方便。","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9943859167","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":261,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9943822636,"gmtCreate":1679363464726,"gmtModify":1679363467419,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9943822636","repostId":"9943861770","repostType":1,"repost":{"id":9943861770,"gmtCreate":1679357959590,"gmtModify":1679362918966,"author":{"id":"10000000000010725","authorId":"10000000000010725","name":"SpicyTrade","avatar":"https://community-static.tradeup.com/news/8625e39315faf7fe99c5d50b5dab2fe6","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"10000000000010725","authorIdStr":"10000000000010725"},"themes":[],"htmlText":"\n \n \n  Welcome to UBS ( $UBS ) stock analysis Date :March 20, 2023 Please note: All stock analysis posted here is for information and ...<a href=\"https://laohu8.com/POSTVIDEO/{ID}\"></a><a href=\"https://www.youtube.com/embed/9V2Z0KnPsMw\">UBS ( $UBS ) stock analysis</a>From Youtube: https://www.youtube.com/watch?v=9V2Z0KnPsMw\n \n","listText":"Welcome to UBS ( $UBS ) stock analysis Date :March 20, 2023 Please note: All stock analysis posted here is for information and ...<a href=\"https://laohu8.com/POSTVIDEO/{ID}\"></a><a href=\"https://www.youtube.com/embed/9V2Z0KnPsMw\">UBS ( $UBS ) stock analysis</a>From Youtube: https://www.youtube.com/watch?v=9V2Z0KnPsMw","text":"Welcome to UBS ( $UBS ) stock analysis Date :March 20, 2023 Please note: All stock analysis posted here is for information and ...UBS ( $UBS ) stock analysisFrom Youtube: https://www.youtube.com/watch?v=9V2Z0KnPsMw","images":[],"top":1,"highlighted":2,"essential":2,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9943861770","isVote":1,"tweetType":2,"object":{"id":"2a7645e8dfd849b183b487436b0a8d24","tweetId":"9943861770","title":"UBS ( $UBS ) stock analysis","videoUrl":"http://v.tigerbbs.com/1679357952384bd7d44573e6878ee9db7cd4619e7539c.mp4","poster":"https://static.tigerbbs.com/ff6700d29edf30c993c4a45290567661","shareLink":"http://v.tigerbbs.com/1679357952384bd7d44573e6878ee9db7cd4619e7539c.mp4"},"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":460,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9943901598,"gmtCreate":1679013113014,"gmtModify":1679013116361,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9943901598","repostId":"2320361770","repostType":4,"repost":{"id":"2320361770","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1679011262,"share":"https://ttm.financial/m/news/2320361770?lang=&edition=fundamental","pubTime":"2023-03-17 08:01","market":"us","language":"en","title":"Microsoft Unveils AI Office Copilot In Fast-Moving Race With Google","url":"https://stock-news.laohu8.com/highlight/detail?id=2320361770","media":"Reuters","summary":"(Reuters) - $Microsoft Corp (MSFT)$ on Thursday trumpeted its latest plans to put artificial intelligence into the hands of more users, answering a spate of unveilings this week by its rival $Google (","content":"<html><head></head><body><p>(Reuters) - <a href=\"https://laohu8.com/S/MSFT\">Microsoft Corp </a> on Thursday trumpeted its latest plans to put artificial intelligence into the hands of more users, answering a spate of unveilings this week by its rival <a href=\"https://laohu8.com/S/GOOGL\">Google </a> with upgrades to its own widely used office software.</p><p>The technology company previewed a new AI &#34;Copilot&#34; for Microsoft 365, its product suite that includes Word documents, Excel spreadsheets, PowerPoint presentations and Outlook emails. First open to some 20 enterprises for testing, AI will offer a draft in these applications, speeding up content creation and freeing up workers&#39; time, Microsoft said.</p><p>The Redmond, Washington-based company, outpacing peers through investments in ChatGPT&#39;s creator OpenAI, also showcased a new &#34;business chat&#34; experience that can pull data and perform tasks across applications on a user&#39;s written command.</p><p>&#34;We believe this next generation of AI will unlock a new wave of productivity growth,&#34; Satya Nadella, Microsoft&#39;s chief executive, said in an online presentation.</p><p>Microsoft&#39;s share price rose about 4% on the news.</p><p>This week&#39;s drumbeat of developments including new funding for AI startup Adept reflects how companies large and small are locked in a fierce competition to deploy software that could reshape how people work.</p><p>At the center are Microsoft and Google-owner Alphabet Inc, which on Tuesday touted AI features for Gmail and a &#34;magic wand&#34; to draft prose in its own word processor. The capabilities that Microsoft and Google showcased are similar.</p><p>The frenzy to invest in and build new products began with last year&#39;s launch of ChatGPT, the chatbot sensation that showed the public the potential of so-called large language models.</p><p>Such technology learns from past data how to create content anew. It has evolved rapidly. Just this week, OpenAI began the release of a more-powerful version known as GPT-4. This partly underpins Microsoft&#39;s Copilot features, along with an older GPT-3.5 model, business and application data, Microsoft said.</p><p>The new capabilities - offered through Microsoft&#39;s cloud - are poised to attract business and turn around slowing revenue growth, RBC analyst Rishi Jaluria said.</p><p>The Copilot will &#34;drive more usage of Microsoft Office and increase the separation versus competitors,&#34; Jaluria said.</p><h3>TAKING NOTES FOR YOU</h3><p>One of the company&#39;s biggest updates on Thursday was in Excel.</p><p>Microsoft said AI can open up the computational wizardry of its spreadsheet software, long the domain of trained analysts, to any person able to describe a calculation they would like in plain text.</p><p>Similar to live notes that Google showed reporters this week, Microsoft said its Copilot can summarize virtual meetings as they happen in its Teams collaboration software.</p><p>In an interview, Jon Friedman, a corporate vice president at Microsoft, demonstrated this capability. The Copilot generated bullet points summarizing questions that Reuters asked, including whether Microsoft can roll out the technology profitably.</p><p>Large language models require lots of computing power and costs to run.</p><p>Friedman said Microsoft will make the deployment work economically.</p><p>The Copilot summarized his answer thus, during the interview: &#34;Microsoft is working on lowering the cost and increasing the speed and fidelity of the models, but did not disclose the pricing or tiring of the copilot system.&#34; (It meant to say &#34;tiering.&#34;)</p><p>Fine-tuning the technology and ensuring that its answers are factual is why Microsoft is testing Copilot with some customers before a wider rollout, Friedman said. An &#34;amazing thing about large language models is they&#39;re very confident, and they get things wrong,&#34; Friedman added.</p><p>Friedman pointed to Microsoft&#39;s business chat experience as the biggest development on Thursday because it can handle tasks across applications. For instance, a user can ask, &#34;Tell my team how we updated the product strategy,&#34; and the AI will take cues from a morning&#39;s worth of emails, meetings and chat threads, Microsoft said.</p><p>Longer-term, Friedman said, the vision is a more personalized AI.</p><p>&#34;We often make people adapt to the machines and systems we have built,&#34; Friedman said. &#34;This is a thing that will start to adapt to you.&#34;</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Microsoft Unveils AI Office Copilot In Fast-Moving Race With Google</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicrosoft Unveils AI Office Copilot In Fast-Moving Race With Google\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2023-03-17 08:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>(Reuters) - <a href=\"https://laohu8.com/S/MSFT\">Microsoft Corp </a> on Thursday trumpeted its latest plans to put artificial intelligence into the hands of more users, answering a spate of unveilings this week by its rival <a href=\"https://laohu8.com/S/GOOGL\">Google </a> with upgrades to its own widely used office software.</p><p>The technology company previewed a new AI &#34;Copilot&#34; for Microsoft 365, its product suite that includes Word documents, Excel spreadsheets, PowerPoint presentations and Outlook emails. First open to some 20 enterprises for testing, AI will offer a draft in these applications, speeding up content creation and freeing up workers&#39; time, Microsoft said.</p><p>The Redmond, Washington-based company, outpacing peers through investments in ChatGPT&#39;s creator OpenAI, also showcased a new &#34;business chat&#34; experience that can pull data and perform tasks across applications on a user&#39;s written command.</p><p>&#34;We believe this next generation of AI will unlock a new wave of productivity growth,&#34; Satya Nadella, Microsoft&#39;s chief executive, said in an online presentation.</p><p>Microsoft&#39;s share price rose about 4% on the news.</p><p>This week&#39;s drumbeat of developments including new funding for AI startup Adept reflects how companies large and small are locked in a fierce competition to deploy software that could reshape how people work.</p><p>At the center are Microsoft and Google-owner Alphabet Inc, which on Tuesday touted AI features for Gmail and a &#34;magic wand&#34; to draft prose in its own word processor. The capabilities that Microsoft and Google showcased are similar.</p><p>The frenzy to invest in and build new products began with last year&#39;s launch of ChatGPT, the chatbot sensation that showed the public the potential of so-called large language models.</p><p>Such technology learns from past data how to create content anew. It has evolved rapidly. Just this week, OpenAI began the release of a more-powerful version known as GPT-4. This partly underpins Microsoft&#39;s Copilot features, along with an older GPT-3.5 model, business and application data, Microsoft said.</p><p>The new capabilities - offered through Microsoft&#39;s cloud - are poised to attract business and turn around slowing revenue growth, RBC analyst Rishi Jaluria said.</p><p>The Copilot will &#34;drive more usage of Microsoft Office and increase the separation versus competitors,&#34; Jaluria said.</p><h3>TAKING NOTES FOR YOU</h3><p>One of the company&#39;s biggest updates on Thursday was in Excel.</p><p>Microsoft said AI can open up the computational wizardry of its spreadsheet software, long the domain of trained analysts, to any person able to describe a calculation they would like in plain text.</p><p>Similar to live notes that Google showed reporters this week, Microsoft said its Copilot can summarize virtual meetings as they happen in its Teams collaboration software.</p><p>In an interview, Jon Friedman, a corporate vice president at Microsoft, demonstrated this capability. The Copilot generated bullet points summarizing questions that Reuters asked, including whether Microsoft can roll out the technology profitably.</p><p>Large language models require lots of computing power and costs to run.</p><p>Friedman said Microsoft will make the deployment work economically.</p><p>The Copilot summarized his answer thus, during the interview: &#34;Microsoft is working on lowering the cost and increasing the speed and fidelity of the models, but did not disclose the pricing or tiring of the copilot system.&#34; (It meant to say &#34;tiering.&#34;)</p><p>Fine-tuning the technology and ensuring that its answers are factual is why Microsoft is testing Copilot with some customers before a wider rollout, Friedman said. An &#34;amazing thing about large language models is they&#39;re very confident, and they get things wrong,&#34; Friedman added.</p><p>Friedman pointed to Microsoft&#39;s business chat experience as the biggest development on Thursday because it can handle tasks across applications. For instance, a user can ask, &#34;Tell my team how we updated the product strategy,&#34; and the AI will take cues from a morning&#39;s worth of emails, meetings and chat threads, Microsoft said.</p><p>Longer-term, Friedman said, the vision is a more personalized AI.</p><p>&#34;We often make people adapt to the machines and systems we have built,&#34; Friedman said. &#34;This is a thing that will start to adapt to you.&#34;</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GOOGL":"谷歌A","MSFT":"微软"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2320361770","content_text":"(Reuters) - Microsoft Corp  on Thursday trumpeted its latest plans to put artificial intelligence into the hands of more users, answering a spate of unveilings this week by its rival Google  with upgrades to its own widely used office software.The technology company previewed a new AI \"Copilot\" for Microsoft 365, its product suite that includes Word documents, Excel spreadsheets, PowerPoint presentations and Outlook emails. First open to some 20 enterprises for testing, AI will offer a draft in these applications, speeding up content creation and freeing up workers' time, Microsoft said.The Redmond, Washington-based company, outpacing peers through investments in ChatGPT's creator OpenAI, also showcased a new \"business chat\" experience that can pull data and perform tasks across applications on a user's written command.\"We believe this next generation of AI will unlock a new wave of productivity growth,\" Satya Nadella, Microsoft's chief executive, said in an online presentation.Microsoft's share price rose about 4% on the news.This week's drumbeat of developments including new funding for AI startup Adept reflects how companies large and small are locked in a fierce competition to deploy software that could reshape how people work.At the center are Microsoft and Google-owner Alphabet Inc, which on Tuesday touted AI features for Gmail and a \"magic wand\" to draft prose in its own word processor. The capabilities that Microsoft and Google showcased are similar.The frenzy to invest in and build new products began with last year's launch of ChatGPT, the chatbot sensation that showed the public the potential of so-called large language models.Such technology learns from past data how to create content anew. It has evolved rapidly. Just this week, OpenAI began the release of a more-powerful version known as GPT-4. This partly underpins Microsoft's Copilot features, along with an older GPT-3.5 model, business and application data, Microsoft said.The new capabilities - offered through Microsoft's cloud - are poised to attract business and turn around slowing revenue growth, RBC analyst Rishi Jaluria said.The Copilot will \"drive more usage of Microsoft Office and increase the separation versus competitors,\" Jaluria said.TAKING NOTES FOR YOUOne of the company's biggest updates on Thursday was in Excel.Microsoft said AI can open up the computational wizardry of its spreadsheet software, long the domain of trained analysts, to any person able to describe a calculation they would like in plain text.Similar to live notes that Google showed reporters this week, Microsoft said its Copilot can summarize virtual meetings as they happen in its Teams collaboration software.In an interview, Jon Friedman, a corporate vice president at Microsoft, demonstrated this capability. The Copilot generated bullet points summarizing questions that Reuters asked, including whether Microsoft can roll out the technology profitably.Large language models require lots of computing power and costs to run.Friedman said Microsoft will make the deployment work economically.The Copilot summarized his answer thus, during the interview: \"Microsoft is working on lowering the cost and increasing the speed and fidelity of the models, but did not disclose the pricing or tiring of the copilot system.\" (It meant to say \"tiering.\")Fine-tuning the technology and ensuring that its answers are factual is why Microsoft is testing Copilot with some customers before a wider rollout, Friedman said. An \"amazing thing about large language models is they're very confident, and they get things wrong,\" Friedman added.Friedman pointed to Microsoft's business chat experience as the biggest development on Thursday because it can handle tasks across applications. For instance, a user can ask, \"Tell my team how we updated the product strategy,\" and the AI will take cues from a morning's worth of emails, meetings and chat threads, Microsoft said.Longer-term, Friedman said, the vision is a more personalized AI.\"We often make people adapt to the machines and systems we have built,\" Friedman said. \"This is a thing that will start to adapt to you.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":187,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9922659030,"gmtCreate":1671760584521,"gmtModify":1676538588840,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9922659030","isVote":1,"tweetType":1,"viewCount":565,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9922959482,"gmtCreate":1671676150447,"gmtModify":1676538574332,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"[Cool]&nbsp;","listText":"[Cool]&nbsp;","text":"[Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9922959482","isVote":1,"tweetType":1,"viewCount":688,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9926558169,"gmtCreate":1671587165151,"gmtModify":1676538560238,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9926558169","isVote":1,"tweetType":1,"viewCount":361,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9926896135,"gmtCreate":1671502668928,"gmtModify":1676538546980,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"[Cool]&nbsp;[Victory]&nbsp;[Strong]&nbsp;","listText":"[Cool]&nbsp;[Victory]&nbsp;[Strong]&nbsp;","text":"[Cool] [Victory] [Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9926896135","isVote":1,"tweetType":1,"viewCount":416,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9928777667,"gmtCreate":1671413741759,"gmtModify":1676538531934,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"[Cool]&nbsp;","listText":"[Cool]&nbsp;","text":"[Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9928777667","isVote":1,"tweetType":1,"viewCount":692,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9928858101,"gmtCreate":1671244911603,"gmtModify":1676538514873,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"🏆","listText":"🏆","text":"🏆","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9928858101","isVote":1,"tweetType":1,"viewCount":277,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9928902183,"gmtCreate":1671158895742,"gmtModify":1676538501333,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"[Victory]&nbsp;","listText":"[Victory]&nbsp;","text":"[Victory]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9928902183","isVote":1,"tweetType":1,"viewCount":401,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9921547365,"gmtCreate":1671101403757,"gmtModify":1676538490235,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"[Cool]&nbsp;⚽️🤑🇦🇷🇫🇷","listText":"[Cool]&nbsp;⚽️🤑🇦🇷🇫🇷","text":"[Cool] ⚽️🤑🇦🇷🇫🇷","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9921547365","isVote":1,"tweetType":1,"viewCount":313,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9921140982,"gmtCreate":1671010780047,"gmtModify":1676538475144,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"⚽️⚽️⚽️","listText":"⚽️⚽️⚽️","text":"⚽️⚽️⚽️","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9921140982","isVote":1,"tweetType":1,"viewCount":383,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9921032073,"gmtCreate":1670935247792,"gmtModify":1676538462138,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"[Cool]&nbsp;","listText":"[Cool]&nbsp;","text":"[Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9921032073","isVote":1,"tweetType":1,"viewCount":332,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9923825434,"gmtCreate":1670830148229,"gmtModify":1676538442107,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$&nbsp;</a><v-v data-views=\"1\"></v-v> [Observation]&nbsp;","listText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$&nbsp;</a><v-v data-views=\"1\"></v-v> [Observation]&nbsp;","text":"$Apple(AAPL)$ [Observation]","images":[{"img":"https://community-static.tradeup.com/news/08207952481fde1ca6ced90877855172","width":"750","height":"1720"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9923825434","isVote":1,"tweetType":1,"viewCount":66,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9923093531,"gmtCreate":1670745073624,"gmtModify":1676538427374,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9923093531","isVote":1,"tweetType":1,"viewCount":285,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9929739071,"gmtCreate":1670728697993,"gmtModify":1676538424485,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$&nbsp;</a><v-v data-views=\"1\"></v-v> [Observation]&nbsp;","listText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$&nbsp;</a><v-v data-views=\"1\"></v-v> [Observation]&nbsp;","text":"$Tesla Motors(TSLA)$ [Observation]","images":[{"img":"https://community-static.tradeup.com/news/329344bb7025c97f189a35b0d76c8976","width":"750","height":"1720"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9929739071","isVote":1,"tweetType":1,"viewCount":91,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9929298435,"gmtCreate":1670668282327,"gmtModify":1676538414881,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9929298435","isVote":1,"tweetType":1,"viewCount":167,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9920743801,"gmtCreate":1670552601404,"gmtModify":1676538392394,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$&nbsp;</a><v-v data-views=\"1\"></v-v> [Observation]&nbsp;","listText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$&nbsp;</a><v-v data-views=\"1\"></v-v> [Observation]&nbsp;","text":"$Apple(AAPL)$ [Observation]","images":[{"img":"https://community-static.tradeup.com/news/2b24222283c36a8cb3b2c2538eb62e4e","width":"750","height":"1720"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9920743801","isVote":1,"tweetType":1,"viewCount":169,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":9938629928,"gmtCreate":1662602235864,"gmtModify":1676537098474,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"Probably yes, as winter is coming soon. The war between Ukraine and Russia is still going on and European countries might&nbsp;face&nbsp;shortages of oil and gas in the months ahead. Riots and unrest in Europe may&nbsp;happen.&nbsp;Supply chain&nbsp;and covid related issues not fully&nbsp;resolved yet. Many more problems might cause stock markets to fluctuate further ....","listText":"Probably yes, as winter is coming soon. The war between Ukraine and Russia is still going on and European countries might&nbsp;face&nbsp;shortages of oil and gas in the months ahead. Riots and unrest in Europe may&nbsp;happen.&nbsp;Supply chain&nbsp;and covid related issues not fully&nbsp;resolved yet. Many more problems might cause stock markets to fluctuate further ....","text":"Probably yes, as winter is coming soon. The war between Ukraine and Russia is still going on and European countries might face shortages of oil and gas in the months ahead. Riots and unrest in Europe may happen. Supply chain and covid related issues not fully resolved yet. Many more problems might cause stock markets to fluctuate further ....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":44,"commentSize":46,"repostSize":0,"link":"https://ttm.financial/post/9938629928","isVote":1,"tweetType":1,"viewCount":1014,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3581902679072107","authorId":"3581902679072107","name":"Ghai","avatar":"https://community-static.tradeup.com/news/0baaa9e9f236fdb0e18da89755b242eb","crmLevel":5,"crmLevelSwitch":1,"idStr":"3581902679072107","authorIdStr":"3581902679072107"},"content":"This depends on which market you are referring to Europe will be deeply affected. Impact on other regions will depend on how the spillover effect Europe may have and individual incidents in the region","text":"This depends on which market you are referring to Europe will be deeply affected. Impact on other regions will depend on how the spillover effect Europe may have and individual incidents in the region","html":"This depends on which market you are referring to Europe will be deeply affected. Impact on other regions will depend on how the spillover effect Europe may have and individual incidents in the region"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9052438657,"gmtCreate":1655201464480,"gmtModify":1676535581555,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"There’s a possibility for Bitcoin price to fall below $20k when inflation is high. As prices for energy and daily necessities keep gg up, how wld ppl hv the extra money to invest in Bitcoin? Probably when inflation is kept under control, then maybe bitcoin will start to move up again ?&nbsp;[Thinking]&nbsp;[Doubt]&nbsp;","listText":"There’s a possibility for Bitcoin price to fall below $20k when inflation is high. As prices for energy and daily necessities keep gg up, how wld ppl hv the extra money to invest in Bitcoin? Probably when inflation is kept under control, then maybe bitcoin will start to move up again ?&nbsp;[Thinking]&nbsp;[Doubt]&nbsp;","text":"There’s a possibility for Bitcoin price to fall below $20k when inflation is high. As prices for energy and daily necessities keep gg up, how wld ppl hv the extra money to invest in Bitcoin? Probably when inflation is kept under control, then maybe bitcoin will start to move up again ? [Thinking] [Doubt]","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":28,"commentSize":0,"repostSize":2,"link":"https://ttm.financial/post/9052438657","isVote":1,"tweetType":1,"viewCount":532,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3572267605406030","authorId":"3572267605406030","name":"Jason1616","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":7,"crmLevelSwitch":0,"idStr":"3572267605406030","authorIdStr":"3572267605406030"},"content":"Institutionals are accumulating. Great manipulation","text":"Institutionals are accumulating. Great manipulation","html":"Institutionals are accumulating. Great manipulation"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9035408271,"gmtCreate":1647649790607,"gmtModify":1676534254834,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$</a>gotta be profitable n&nbsp;responsible to shareholders as well as to be able to survive in the current competitive market ....","listText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$</a>gotta be profitable n&nbsp;responsible to shareholders as well as to be able to survive in the current competitive market ....","text":"$Tesla Motors(TSLA)$gotta be profitable n responsible to shareholders as well as to be able to survive in the current competitive market ....","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":24,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035408271","repostId":"9035331839","repostType":1,"repost":{"id":9035331839,"gmtCreate":1647505659604,"gmtModify":1676534238608,"author":{"id":"9000000000000175","authorId":"9000000000000175","name":"HenryHoward","avatar":"https://static.tigerbbs.com/0f379c0439dbd36ed017761896cd91f0","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"9000000000000175","authorIdStr":"9000000000000175"},"themes":[],"title":"Tesla Stock Is Fully Priced At These Levels","htmlText":"Thesis What brought Tesla, Inc. ($TSLA) to my attention was a common characteristic that it shares with the midstream sector in the oil and gas industry, the midstream sector being the pipeline companies that transport hydrocarbons from the wellhead to downstream users. It's an area about which I have written a lot and currently favor. And similar to midstream operators, Tesla faces an extremely strong demand environment whereby everything it produces it can sell. There's currently no demand constraint to the company's growth, meaning that the company's primary obstacle is not demand creation but rather the speed at which it can add supply capacity to meet that demand. In analyzing Tesla's stock and growth prospects, that means the emphasis needs to be on Operating Cash Flow (\"OCF\"), not F","listText":"Thesis What brought Tesla, Inc. ($TSLA) to my attention was a common characteristic that it shares with the midstream sector in the oil and gas industry, the midstream sector being the pipeline companies that transport hydrocarbons from the wellhead to downstream users. It's an area about which I have written a lot and currently favor. And similar to midstream operators, Tesla faces an extremely strong demand environment whereby everything it produces it can sell. There's currently no demand constraint to the company's growth, meaning that the company's primary obstacle is not demand creation but rather the speed at which it can add supply capacity to meet that demand. In analyzing Tesla's stock and growth prospects, that means the emphasis needs to be on Operating Cash Flow (\"OCF\"), not F","text":"Thesis What brought Tesla, Inc. ($TSLA) to my attention was a common characteristic that it shares with the midstream sector in the oil and gas industry, the midstream sector being the pipeline companies that transport hydrocarbons from the wellhead to downstream users. It's an area about which I have written a lot and currently favor. And similar to midstream operators, Tesla faces an extremely strong demand environment whereby everything it produces it can sell. There's currently no demand constraint to the company's growth, meaning that the company's primary obstacle is not demand creation but rather the speed at which it can add supply capacity to meet that demand. In analyzing Tesla's stock and growth prospects, that means the emphasis needs to be on Operating Cash Flow (\"OCF\"), not F","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9035331839","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":343,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000652","authorId":"9000000000000652","name":"ChristKitto","avatar":"https://static.tigerbbs.com/4978f4a510bcf43d5d844a52ae86fd92","crmLevel":1,"crmLevelSwitch":0,"idStr":"9000000000000652","authorIdStr":"9000000000000652"},"content":"wait I’m confused it was quad witching today I thought that meant volatility we went straight up basically","text":"wait I’m confused it was quad witching today I thought that meant volatility we went straight up basically","html":"wait I’m confused it was quad witching today I thought that meant volatility we went straight up basically"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9037012220,"gmtCreate":1647992207497,"gmtModify":1676534288979,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"The increase of stock repurchase for $Alibaba(BABA)$ could imply tat the company is confident in their biz and they hv the Cash to buy back especially when the stock value is low compared to its ATH …. the rebound of the stock can&nbsp;be short term but the effect could&nbsp;be long term ....&nbsp;[Thinking]&nbsp;[Observation]&nbsp;","listText":"The increase of stock repurchase for $Alibaba(BABA)$ could imply tat the company is confident in their biz and they hv the Cash to buy back especially when the stock value is low compared to its ATH …. the rebound of the stock can&nbsp;be short term but the effect could&nbsp;be long term ....&nbsp;[Thinking]&nbsp;[Observation]&nbsp;","text":"The increase of stock repurchase for $Alibaba(BABA)$ could imply tat the company is confident in their biz and they hv the Cash to buy back especially when the stock value is low compared to its ATH …. the rebound of the stock can be short term but the effect could be long term .... [Thinking] [Observation]","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":12,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9037012220","repostId":"9034401981","repostType":1,"repost":{"id":9034401981,"gmtCreate":1647933878091,"gmtModify":1676534281814,"author":{"id":"3501196737273098","authorId":"3501196737273098","name":"Tiger_comments","avatar":"https://community-static.tradeup.com/news/227887b200e9925968650d5db4a8bfb3","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3501196737273098","authorIdStr":"3501196737273098"},"themes":[],"title":"The largest Buyback of Chinese stocks: Alibaba $25 billion!","htmlText":" On March 22, Alibaba announced: Increase the scale of stock repurchase from $15 billion to $25 billion. It is reported that: As of March 18, 2022, Alibaba has repurchased 56.2 million American depositary shares, valued at approximately $9.2 billion. This time, the repurchase scale was increased to US $25 billion, setting a record high for the repurchase amount of China Stocks, reflecting Ali's confidence in sustained growth in the future. Some analysts said: China concept stocks are at historically low levels, and repurchasing stocks will stimulate stock prices to rise, and a large-scale repurchase of China concept stocks may be about to begin. Veteran <a target=\"_blank\" href=\"https://laohu8.com/U/3502860692623653\">@Violence_Panda</a> says: The rebound of Chinese concept stocks i","listText":" On March 22, Alibaba announced: Increase the scale of stock repurchase from $15 billion to $25 billion. It is reported that: As of March 18, 2022, Alibaba has repurchased 56.2 million American depositary shares, valued at approximately $9.2 billion. This time, the repurchase scale was increased to US $25 billion, setting a record high for the repurchase amount of China Stocks, reflecting Ali's confidence in sustained growth in the future. Some analysts said: China concept stocks are at historically low levels, and repurchasing stocks will stimulate stock prices to rise, and a large-scale repurchase of China concept stocks may be about to begin. Veteran <a target=\"_blank\" href=\"https://laohu8.com/U/3502860692623653\">@Violence_Panda</a> says: The rebound of Chinese concept stocks i","text":"On March 22, Alibaba announced: Increase the scale of stock repurchase from $15 billion to $25 billion. It is reported that: As of March 18, 2022, Alibaba has repurchased 56.2 million American depositary shares, valued at approximately $9.2 billion. This time, the repurchase scale was increased to US $25 billion, setting a record high for the repurchase amount of China Stocks, reflecting Ali's confidence in sustained growth in the future. Some analysts said: China concept stocks are at historically low levels, and repurchasing stocks will stimulate stock prices to rise, and a large-scale repurchase of China concept stocks may be about to begin. Veteran @Violence_Panda says: The rebound of Chinese concept stocks i","images":[{"img":"https://static.tigerbbs.com/0172fe53a6e0a5775703edc267d6061f","width":"769","height":"385"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9034401981","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"subType":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":336,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000652","authorId":"9000000000000652","name":"ChristKitto","avatar":"https://static.tigerbbs.com/4978f4a510bcf43d5d844a52ae86fd92","crmLevel":1,"crmLevelSwitch":0,"idStr":"9000000000000652","authorIdStr":"9000000000000652"},"content":"I was checking their financials , this is really cheap. If they don’t do anything stupid we can easily see $200 here","text":"I was checking their financials , this is really cheap. If they don’t do anything stupid we can easily see $200 here","html":"I was checking their financials , this is really cheap. If they don’t do anything stupid we can easily see $200 here"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9015775660,"gmtCreate":1649559215821,"gmtModify":1676534530382,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"Majority of ppl love&nbsp;or like money. Why ppl wanna start investing or trading? For money,I guess ....coz by investing, u can make moremoney and earn faster than u go to work as the&nbsp;money works for U! With money, u got the option to stop working and enjoy better lifestyle. U got the freedom to choose to work or not to work. The reasons to invest or totrade can be never ending ....","listText":"Majority of ppl love&nbsp;or like money. Why ppl wanna start investing or trading? For money,I guess ....coz by investing, u can make moremoney and earn faster than u go to work as the&nbsp;money works for U! With money, u got the option to stop working and enjoy better lifestyle. U got the freedom to choose to work or not to work. The reasons to invest or totrade can be never ending ....","text":"Majority of ppl love or like money. Why ppl wanna start investing or trading? For money,I guess ....coz by investing, u can make moremoney and earn faster than u go to work as the money works for U! With money, u got the option to stop working and enjoy better lifestyle. U got the freedom to choose to work or not to work. The reasons to invest or totrade can be never ending ....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/9015775660","isVote":1,"tweetType":1,"viewCount":193,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000652","authorId":"9000000000000652","name":"ChristKitto","avatar":"https://static.tigerbbs.com/4978f4a510bcf43d5d844a52ae86fd92","crmLevel":1,"crmLevelSwitch":0,"idStr":"9000000000000652","authorIdStr":"9000000000000652"},"content":"It goes without saying! The author's views represent the aspirations of the vast majority of people, hoping to make it easier to make money by investing in stocks.","text":"It goes without saying! The author's views represent the aspirations of the vast majority of people, hoping to make it easier to make money by investing in stocks.","html":"It goes without saying! The author's views represent the aspirations of the vast majority of people, hoping to make it easier to make money by investing in stocks."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9947256847,"gmtCreate":1683218120289,"gmtModify":1683218124039,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947256847","repostId":"9947269379","repostType":1,"repost":{"id":9947269379,"gmtCreate":1683198790891,"gmtModify":1683198818640,"author":{"id":"4115188532413322","authorId":"4115188532413322","name":"Tiger_Wealth","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4115188532413322","authorIdStr":"4115188532413322"},"themes":[],"title":"25bps Rate Hike in May’s FOMC Meeting: Fed Pause on The Horizon","htmlText":"In a widely anticipated move, the US Federal Reserve raised interest rates for the 10th time in just over a year. The Fed fund rate now stands at a target range of 5%-5.25%, which is the highest it has been since August 2007.Source: Bloomberg&nbsp;During the news conference that followed the meeting, Chairman Jerome Powell confirmed that \"a decision on a pause was not made today.\" This is despite the omission of a sentence stating that “the Committee anticipates that some additional policy firming may be appropriate.\" It appears that the Fed has finally reached the terminal rates it had set out to achieve.&nbsp;S&amp;P 500 &amp; Nasdaq Index, Source: Bloomberg The bond markets initially priced a rate hike in the June Fed meeting. However, the sentiment soon changed into a likely rate pause","listText":"In a widely anticipated move, the US Federal Reserve raised interest rates for the 10th time in just over a year. The Fed fund rate now stands at a target range of 5%-5.25%, which is the highest it has been since August 2007.Source: Bloomberg&nbsp;During the news conference that followed the meeting, Chairman Jerome Powell confirmed that \"a decision on a pause was not made today.\" This is despite the omission of a sentence stating that “the Committee anticipates that some additional policy firming may be appropriate.\" It appears that the Fed has finally reached the terminal rates it had set out to achieve.&nbsp;S&amp;P 500 &amp; Nasdaq Index, Source: Bloomberg The bond markets initially priced a rate hike in the June Fed meeting. However, the sentiment soon changed into a likely rate pause","text":"In a widely anticipated move, the US Federal Reserve raised interest rates for the 10th time in just over a year. The Fed fund rate now stands at a target range of 5%-5.25%, which is the highest it has been since August 2007.Source: Bloomberg During the news conference that followed the meeting, Chairman Jerome Powell confirmed that \"a decision on a pause was not made today.\" This is despite the omission of a sentence stating that “the Committee anticipates that some additional policy firming may be appropriate.\" It appears that the Fed has finally reached the terminal rates it had set out to achieve. S&P 500 & Nasdaq Index, Source: Bloomberg The bond markets initially priced a rate hike in the June Fed meeting. However, the sentiment soon changed into a likely rate pause","images":[{"img":"https://community-static.tradeup.com/news/80116eeef27dd0f8dcbc4361429d763c","width":"752","height":"462"},{"img":"https://community-static.tradeup.com/news/8c180491c8a6d0bbb5ee2b75e1104e29","width":"761","height":"453"},{"img":"https://community-static.tradeup.com/news/e630ae790463ff9fb94d3927639fc388","width":"774","height":"438"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9947269379","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":4,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":350,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9039109067,"gmtCreate":1645936285005,"gmtModify":1676534076433,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"Investors shd cherish the opportunities on the ride with <a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$</a>instead ....","listText":"Investors shd cherish the opportunities on the ride with <a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$</a>instead ....","text":"Investors shd cherish the opportunities on the ride with $Tesla Motors(TSLA)$instead ....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9039109067","repostId":"636127274","repostType":1,"repost":{"id":636127274,"gmtCreate":1645712905074,"gmtModify":1676532764941,"author":{"id":"3477399047065723","authorId":"3477399047065723","name":"MRSHE","avatar":"https://static.tigerbbs.com/4f08fde92ea1aa0a1180068bcd298d91","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3477399047065723","authorIdStr":"3477399047065723"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$</a>珍惜900一下的機會，珍惜800以下的機會，珍惜700以下的機會，.....這沒完沒了了","listText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$</a>珍惜900一下的機會，珍惜800以下的機會，珍惜700以下的機會，.....這沒完沒了了","text":"$特斯拉(TSLA)$珍惜900一下的機會，珍惜800以下的機會，珍惜700以下的機會，.....這沒完沒了了","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/636127274","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1117,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3571881968134546","authorId":"3571881968134546","name":"TCT","avatar":"https://static.tigerbbs.com/817788e0e4214dd64f6bc2d3e0bea2eb","crmLevel":5,"crmLevelSwitch":1,"idStr":"3571881968134546","authorIdStr":"3571881968134546"},"content":"face a tough era in 2022?","text":"face a tough era in 2022?","html":"face a tough era in 2022?"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814131239,"gmtCreate":1630792705221,"gmtModify":1676530393977,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"It needs to keep innovate to stay competitive over the long run …Pls comment and like. Thanks.&nbsp;","listText":"It needs to keep innovate to stay competitive over the long run …Pls comment and like. Thanks.&nbsp;","text":"It needs to keep innovate to stay competitive over the long run …Pls comment and like. Thanks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/814131239","repostId":"1128877475","repostType":4,"repost":{"id":"1128877475","pubTimestamp":1630681596,"share":"https://ttm.financial/m/news/1128877475?lang=&edition=fundamental","pubTime":"2021-09-03 23:06","market":"us","language":"en","title":"Facebook prospects remain bright despite stock run-up - Rowan Street Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=1128877475","media":"seekingalpha","summary":"Alex Kopel and Joe Maas, co-founders and managing directors at Rowan Street Capital, said in a lette","content":"<ul>\n <li>Alex Kopel and Joe Maas, co-founders and managing directors at Rowan Street Capital, said in a letter to investors that the \"future prospects remain bright\" for Facebook(NASDAQ:FB), despite the fact that the fund's investment in the social media platform has already doubled over the past three years.</li>\n <li>\"We were convinced that FB remains an extraordinary business with an incredible moat (2.9B users), and they still have tons of opportunities to profitably reinvest their capital,\" they said&nbsp;in a fund letter released this week.</li>\n <li>Kopel and Maas acknowledged that the company has been forced to increase its expenses in recent years to answer regulatory concerns and to counter worries about misinformation on its platform.</li>\n <li>However, they expect future expense growth to approximate revenue growth over time.</li>\n <li>The Rowan Street co-founders predicted that FB would continue to see revenue growth of at least 20%.</li>\n <li>In its latest earnings report, released in late July, FB reported a quarterly profit that&nbsp;easily topped expectations, on revenue that climbed nearly 56% to just over $29B.</li>\n <li>However, the company also warned that&nbsp;revenue growth would significantly decelerate&nbsp;as it comes up against more difficult comparisons.</li>\n <li>FB has advanced steadily since March, reaching a series of 52-week highs. This included a peak of $384.33 set earlier this week. Shares were up fractionally in Friday's intraday action, rising to $376.69:</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Facebook prospects remain bright despite stock run-up - Rowan Street Capital</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFacebook prospects remain bright despite stock run-up - Rowan Street Capital\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 23:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3737186-facebook-prospects-remain-bright-despite-stock-run-up-rowan-street-capital><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alex Kopel and Joe Maas, co-founders and managing directors at Rowan Street Capital, said in a letter to investors that the \"future prospects remain bright\" for Facebook(NASDAQ:FB), despite the fact ...</p>\n\n<a href=\"https://seekingalpha.com/news/3737186-facebook-prospects-remain-bright-despite-stock-run-up-rowan-street-capital\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/news/3737186-facebook-prospects-remain-bright-despite-stock-run-up-rowan-street-capital","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1128877475","content_text":"Alex Kopel and Joe Maas, co-founders and managing directors at Rowan Street Capital, said in a letter to investors that the \"future prospects remain bright\" for Facebook(NASDAQ:FB), despite the fact that the fund's investment in the social media platform has already doubled over the past three years.\n\"We were convinced that FB remains an extraordinary business with an incredible moat (2.9B users), and they still have tons of opportunities to profitably reinvest their capital,\" they said in a fund letter released this week.\nKopel and Maas acknowledged that the company has been forced to increase its expenses in recent years to answer regulatory concerns and to counter worries about misinformation on its platform.\nHowever, they expect future expense growth to approximate revenue growth over time.\nThe Rowan Street co-founders predicted that FB would continue to see revenue growth of at least 20%.\nIn its latest earnings report, released in late July, FB reported a quarterly profit that easily topped expectations, on revenue that climbed nearly 56% to just over $29B.\nHowever, the company also warned that revenue growth would significantly decelerate as it comes up against more difficult comparisons.\nFB has advanced steadily since March, reaching a series of 52-week highs. This included a peak of $384.33 set earlier this week. Shares were up fractionally in Friday's intraday action, rising to $376.69:","news_type":1},"isVote":1,"tweetType":1,"viewCount":247,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":818390943,"gmtCreate":1630374108882,"gmtModify":1676530284127,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"Indeed, when Fed starts to taper, it’s important for companies to hv cash on hand to weather against the competitive marketPls like and comment. Thanks.&nbsp;","listText":"Indeed, when Fed starts to taper, it’s important for companies to hv cash on hand to weather against the competitive marketPls like and comment. Thanks.&nbsp;","text":"Indeed, when Fed starts to taper, it’s important for companies to hv cash on hand to weather against the competitive marketPls like and comment. Thanks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/818390943","repostId":"1181079166","repostType":4,"repost":{"id":"1181079166","pubTimestamp":1630371166,"share":"https://ttm.financial/m/news/1181079166?lang=&edition=fundamental","pubTime":"2021-08-31 08:52","market":"us","language":"en","title":"9 Cash-Rich Stocks That Can Better Weather the Fed’s Taper Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=1181079166","media":"Barron's","summary":"Investors have been waiting for the Federal Reserve to rein in its monetary support as the economy s","content":"<p>Investors have been waiting for the Federal Reserve to rein in its monetary support as the economy stays on track for a healthy rebound from the Covid-19 pandemic.</p>\n<p>In response to the pandemic last year, the Fed launched an emergency bond-buying program that includes $120 billion in monthly purchase of Treasury and mortgage-backed securities purchases. At the central bank’s virtual Jackson Hole conference on Friday, Fed Chairman Jerome Powell reiterated that a taper—the term referring to the Fed’s wind-down of asset purchasing—might be coming by the end of this year. Many analysts expect Powell to offer more details at the Federal Open Market Committee’s September or November meetings.</p>\n<p>Although Powell has struck a relatively dovish tone on the tapering plan, some worry that both the stock and bond markets could see some volatility following the move in a “taper tantrum.”</p>\n<p>Still, even if there is such a selloff, some stocks would survive better than others. The last time the Fed slowed down its pace of bond buying, in May 2013, the best-performing sectors in the following months were materials and industrials.</p>\n<p>This time around, these sectors have even more tailwinds behind them. The $1.2 trillion Infrastructure Investment and Jobs Act has recently passed the Senate. If passed by the House and signed into law, the act will give companies in the material and industrial sector a significant revenue boost in the next few years. This could offset some of the headwinds from the Fed.</p>\n<p>Less Fed money in the market could cause trouble for companies that are tight on cash and reliant on funds raised from the bond market. Within these sectors, investors should look for companies that have more cash on their balance sheets and can make efficient use of them.</p>\n<p>Barron’s screened for S&amp;P 500 stocks within the industrial and material sectors that meet three criteria:</p>\n<ul>\n <li>Cash flow per share, which indicates how much cash a company generates for each outstanding share. For the purposes of our screen, it needed to be more than 10.</li>\n <li>The share price to cash flow, indicating how much investors pay for every dollar of cash flow, which needed to be lower than 20;</li>\n <li>The return on equity, which determines how much profit a company earns for every dollar of asset and which needed to be more than 30.</li>\n</ul>\n<p>This has left us with nine names that are rich in cash and efficient with their capital deployment. They are more likely to continue marching ahead even when the Fed takes its feet off the gas. Wall Street consensus shows that analysts expect to see more upside in all these stocks in the next 12 months.</p>\n<p>The nine are: United Parcel Service (UPS), Union Pacific (UNP), Deere (DE), 3M (MMM), Lockheed Martin (LMT), Northrop Grumman (NOC), LyondellBasell Industries (LYB), W.W. Grainger (GWW), and Celanese (CE).</p>\n<p><img src=\"https://static.tigerbbs.com/b7fc6f35ee6d688711cdc84408c9c7bc\" tg-width=\"2600\" tg-height=\"900\" width=\"100%\" height=\"auto\"></p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>9 Cash-Rich Stocks That Can Better Weather the Fed’s Taper Risks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n9 Cash-Rich Stocks That Can Better Weather the Fed’s Taper Risks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-31 08:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/stocks-that-can-weather-fed-taper-risks-51630171767?siteid=yhoof2><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors have been waiting for the Federal Reserve to rein in its monetary support as the economy stays on track for a healthy rebound from the Covid-19 pandemic.\nIn response to the pandemic last ...</p>\n\n<a href=\"https://www.barrons.com/articles/stocks-that-can-weather-fed-taper-risks-51630171767?siteid=yhoof2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UNP":"联合太平洋","UPS":"联合包裹","GWW":"美国固安捷","MMM":"3M","NOC":"诺斯罗普格鲁曼","CE":"塞拉尼斯","LMT":"洛克希德马丁","DE":"迪尔股份有限公司","LYB":"利安德巴塞尔"},"source_url":"https://www.barrons.com/articles/stocks-that-can-weather-fed-taper-risks-51630171767?siteid=yhoof2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1181079166","content_text":"Investors have been waiting for the Federal Reserve to rein in its monetary support as the economy stays on track for a healthy rebound from the Covid-19 pandemic.\nIn response to the pandemic last year, the Fed launched an emergency bond-buying program that includes $120 billion in monthly purchase of Treasury and mortgage-backed securities purchases. At the central bank’s virtual Jackson Hole conference on Friday, Fed Chairman Jerome Powell reiterated that a taper—the term referring to the Fed’s wind-down of asset purchasing—might be coming by the end of this year. Many analysts expect Powell to offer more details at the Federal Open Market Committee’s September or November meetings.\nAlthough Powell has struck a relatively dovish tone on the tapering plan, some worry that both the stock and bond markets could see some volatility following the move in a “taper tantrum.”\nStill, even if there is such a selloff, some stocks would survive better than others. The last time the Fed slowed down its pace of bond buying, in May 2013, the best-performing sectors in the following months were materials and industrials.\nThis time around, these sectors have even more tailwinds behind them. The $1.2 trillion Infrastructure Investment and Jobs Act has recently passed the Senate. If passed by the House and signed into law, the act will give companies in the material and industrial sector a significant revenue boost in the next few years. This could offset some of the headwinds from the Fed.\nLess Fed money in the market could cause trouble for companies that are tight on cash and reliant on funds raised from the bond market. Within these sectors, investors should look for companies that have more cash on their balance sheets and can make efficient use of them.\nBarron’s screened for S&P 500 stocks within the industrial and material sectors that meet three criteria:\n\nCash flow per share, which indicates how much cash a company generates for each outstanding share. For the purposes of our screen, it needed to be more than 10.\nThe share price to cash flow, indicating how much investors pay for every dollar of cash flow, which needed to be lower than 20;\nThe return on equity, which determines how much profit a company earns for every dollar of asset and which needed to be more than 30.\n\nThis has left us with nine names that are rich in cash and efficient with their capital deployment. They are more likely to continue marching ahead even when the Fed takes its feet off the gas. Wall Street consensus shows that analysts expect to see more upside in all these stocks in the next 12 months.\nThe nine are: United Parcel Service (UPS), Union Pacific (UNP), Deere (DE), 3M (MMM), Lockheed Martin (LMT), Northrop Grumman (NOC), LyondellBasell Industries (LYB), W.W. Grainger (GWW), and Celanese (CE).","news_type":1},"isVote":1,"tweetType":1,"viewCount":91,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9088631583,"gmtCreate":1650336206734,"gmtModify":1676534699702,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"No more easy salary for board members if Elon Musk&nbsp;successfully takeover TWTR ....&nbsp;[Miser]&nbsp;[USD]&nbsp;[Onlooker]&nbsp;","listText":"No more easy salary for board members if Elon Musk&nbsp;successfully takeover TWTR ....&nbsp;[Miser]&nbsp;[USD]&nbsp;[Onlooker]&nbsp;","text":"No more easy salary for board members if Elon Musk successfully takeover TWTR .... [Miser] [USD] [Onlooker]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9088631583","repostId":"1194995628","repostType":2,"repost":{"id":"1194995628","pubTimestamp":1650334521,"share":"https://ttm.financial/m/news/1194995628?lang=&edition=fundamental","pubTime":"2022-04-19 10:15","market":"us","language":"en","title":"What Is a Tender Offer in Stocks and What Would One Mean for TWTR?","url":"https://stock-news.laohu8.com/highlight/detail?id=1194995628","media":"InvestorPlace","summary":"Elon Musk's 'Plan B' may be a tender offer","content":"<html><head></head><body><p>Over the weekend,<b>Twitter’s</b>(NYSE:<b><u>TWTR</u></b>) board of directors enacted a poison pill plan. The plan allows Twitter to give existing shareholders the right to purchase shares at a discount. This plan will be triggered if an entity purchases at least 15% of TWTR stock without the approval of the board. In other words, it’s very clear that Twitter’s board does not want Elon Musk to acquire the company.</p><p>Despite the board’s disapproval, Musk has stated himself that he has a “Plan B.” On Saturday, Musk then tweeted out “Love Me Tender,” a reference to Elvis Presley’s 1956 hit song.</p><p>However, investors are speculating that Musk was actually hinting at a tender offer for his Plan B. So, what exactly is a tender offer?</p><p><b>What Is a Tender Offer?</b></p><p>A tender offer is an offer to a company’s shareholders instead of the board. The offer is usually priced significantly above the current market price. These offers typically look to acquire stock from shareholders at a specific price and within a specified period of time. The acquirer does this in order to own a majority stake in the target company.</p><p>In the case of a takeover attempt, which Musk may choose to pursue, the offer may be conditional “on the prospective buyer being able to obtain a certain amount of shares.” In addition, the acquirer does not need the board’s approval to enact a tender offer.</p><p>An advantage of a tender offer is that the acquirer does not need to raise money right away. Rather, the acquirer can wait to buy shares “until a set number is tendered.” Acquirers can also enact escape clauses, which would remove liability from buying shares under certain circumstances. A disadvantage is that acquirers must pay associated fees to parties such as the U.S. Securities and Exchange Commission (SEC), attorneys and depository banks.</p><p><b>What Would a Tender Offer Mean for Twitter?</b></p><p>In order for a tender offer to be successful, the acquirer must purchase a certain amount of shares from willing shareholders. In the case of a successful acquisition, Musk tweeted out that he would reduce the board’s salary to $0, which he said would save roughly $3 million per year. Additionally, Twitter would likely experience a major change in leadership, employee count and internal operations.</p><p><img src=\"https://static.tigerbbs.com/f3fb8bb468a24b68ba5ff17c4e987e3f\" tg-width=\"505\" tg-height=\"764\" width=\"100%\" height=\"auto\"/></p><p>Board member and former CEO Jack Dorsey seems to be on Musk’s side. Hetweetedthat the board has “consistently been the dysfunction of the company.” Dorsey’s term on the board expires this May.</p><p><img src=\"https://static.tigerbbs.com/6056255aab757f33b6273909ff6873c6\" tg-width=\"754\" tg-height=\"591\" width=\"100%\" height=\"auto\"/></p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Is a Tender Offer in Stocks and What Would One Mean for TWTR?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Is a Tender Offer in Stocks and What Would One Mean for TWTR?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-19 10:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/what-is-a-tender-offer-in-stocks-and-what-would-one-mean-for-twtr/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Over the weekend,Twitter’s(NYSE:TWTR) board of directors enacted a poison pill plan. The plan allows Twitter to give existing shareholders the right to purchase shares at a discount. This plan will be...</p>\n\n<a href=\"https://investorplace.com/2022/04/what-is-a-tender-offer-in-stocks-and-what-would-one-mean-for-twtr/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TWTR":"Twitter"},"source_url":"https://investorplace.com/2022/04/what-is-a-tender-offer-in-stocks-and-what-would-one-mean-for-twtr/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194995628","content_text":"Over the weekend,Twitter’s(NYSE:TWTR) board of directors enacted a poison pill plan. The plan allows Twitter to give existing shareholders the right to purchase shares at a discount. This plan will be triggered if an entity purchases at least 15% of TWTR stock without the approval of the board. In other words, it’s very clear that Twitter’s board does not want Elon Musk to acquire the company.Despite the board’s disapproval, Musk has stated himself that he has a “Plan B.” On Saturday, Musk then tweeted out “Love Me Tender,” a reference to Elvis Presley’s 1956 hit song.However, investors are speculating that Musk was actually hinting at a tender offer for his Plan B. So, what exactly is a tender offer?What Is a Tender Offer?A tender offer is an offer to a company’s shareholders instead of the board. The offer is usually priced significantly above the current market price. These offers typically look to acquire stock from shareholders at a specific price and within a specified period of time. The acquirer does this in order to own a majority stake in the target company.In the case of a takeover attempt, which Musk may choose to pursue, the offer may be conditional “on the prospective buyer being able to obtain a certain amount of shares.” In addition, the acquirer does not need the board’s approval to enact a tender offer.An advantage of a tender offer is that the acquirer does not need to raise money right away. Rather, the acquirer can wait to buy shares “until a set number is tendered.” Acquirers can also enact escape clauses, which would remove liability from buying shares under certain circumstances. A disadvantage is that acquirers must pay associated fees to parties such as the U.S. Securities and Exchange Commission (SEC), attorneys and depository banks.What Would a Tender Offer Mean for Twitter?In order for a tender offer to be successful, the acquirer must purchase a certain amount of shares from willing shareholders. In the case of a successful acquisition, Musk tweeted out that he would reduce the board’s salary to $0, which he said would save roughly $3 million per year. Additionally, Twitter would likely experience a major change in leadership, employee count and internal operations.Board member and former CEO Jack Dorsey seems to be on Musk’s side. Hetweetedthat the board has “consistently been the dysfunction of the company.” Dorsey’s term on the board expires this May.","news_type":1},"isVote":1,"tweetType":1,"viewCount":183,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9018969770,"gmtCreate":1648958192091,"gmtModify":1676534428613,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"Eat moderately is better and healthier i supposed …. [Thinking]//<a href=\"https://laohu8.com/U/3559581955535845\">@koolgal</a>:Truth is stranger than Fiction!&nbsp; &nbsp; I am a health nut and recently read that there is a diet that allows&nbsp;you to&nbsp;eat all the ice creams and pizzas you want and even throw away your weighing machine.&nbsp; &nbsp;Wow!&nbsp; That's incredible I thought.But yes that is the Truth!&nbsp; Welcome to the Anti Diet Revolution.&nbsp; &nbsp;There is no single diet rule to follow.&nbsp; There is No restriction on what you eat.&nbsp; You can eat all your favourite junk food but the focus is on Intuitive Eating.&nbsp; That means eating according to hunger/fullness level and enjoying the food you eat.&nbsp; The focus is on satisfaction, giving yourself permission","listText":"Eat moderately is better and healthier i supposed …. [Thinking]//<a href=\"https://laohu8.com/U/3559581955535845\">@koolgal</a>:Truth is stranger than Fiction!&nbsp; &nbsp; I am a health nut and recently read that there is a diet that allows&nbsp;you to&nbsp;eat all the ice creams and pizzas you want and even throw away your weighing machine.&nbsp; &nbsp;Wow!&nbsp; That's incredible I thought.But yes that is the Truth!&nbsp; Welcome to the Anti Diet Revolution.&nbsp; &nbsp;There is no single diet rule to follow.&nbsp; There is No restriction on what you eat.&nbsp; You can eat all your favourite junk food but the focus is on Intuitive Eating.&nbsp; That means eating according to hunger/fullness level and enjoying the food you eat.&nbsp; The focus is on satisfaction, giving yourself permission","text":"Eat moderately is better and healthier i supposed …. [Thinking]//@koolgal:Truth is stranger than Fiction! I am a health nut and recently read that there is a diet that allows you to eat all the ice creams and pizzas you want and even throw away your weighing machine. Wow! That's incredible I thought.But yes that is the Truth! Welcome to the Anti Diet Revolution. There is no single diet rule to follow. There is No restriction on what you eat. You can eat all your favourite junk food but the focus is on Intuitive Eating. That means eating according to hunger/fullness level and enjoying the food you eat. The focus is on satisfaction, giving yourself permission","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9018969770","repostId":"9011908737","repostType":1,"repost":{"id":9011908737,"gmtCreate":1648797229768,"gmtModify":1676534400095,"author":{"id":"3527667667103859","authorId":"3527667667103859","name":"TigerEvents","avatar":"https://community-static.tradeup.com/news/c266ef25181ace18bec1262357bbe1a8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667667103859","authorIdStr":"3527667667103859"},"themes":[],"title":"April Fools' Day Special: Find Real Stories that Look Like Pranks","htmlText":"Share real stories that look like pranks &amp; Win Tiger Coins. On April Fools' Day, newspapers and PR agencies have once again celebrated 1 April by publishing made-up stories and press releases. As we live in turbulent times, the boundary between real and fake news is increasingly blurred.Do you know any stories that look like pranks but are not? Please share them in the comment section of this post. Of course, you may also \"make up\" dramatic stories in the comment section of this post. 🎁Prizes All Tigers who comment on this post will receive 50 Tiger Coins. All Tigers who repost and tag their friends in the comment section will receive 10 Tiger Coins for each friend who participates in this event ( Up to 30 friends). One Tiger will be rewarded 1000 coins for the comments with the Most L","listText":"Share real stories that look like pranks &amp; Win Tiger Coins. On April Fools' Day, newspapers and PR agencies have once again celebrated 1 April by publishing made-up stories and press releases. As we live in turbulent times, the boundary between real and fake news is increasingly blurred.Do you know any stories that look like pranks but are not? Please share them in the comment section of this post. Of course, you may also \"make up\" dramatic stories in the comment section of this post. 🎁Prizes All Tigers who comment on this post will receive 50 Tiger Coins. All Tigers who repost and tag their friends in the comment section will receive 10 Tiger Coins for each friend who participates in this event ( Up to 30 friends). One Tiger will be rewarded 1000 coins for the comments with the Most L","text":"Share real stories that look like pranks & Win Tiger Coins. On April Fools' Day, newspapers and PR agencies have once again celebrated 1 April by publishing made-up stories and press releases. As we live in turbulent times, the boundary between real and fake news is increasingly blurred.Do you know any stories that look like pranks but are not? Please share them in the comment section of this post. Of course, you may also \"make up\" dramatic stories in the comment section of this post. 🎁Prizes All Tigers who comment on this post will receive 50 Tiger Coins. All Tigers who repost and tag their friends in the comment section will receive 10 Tiger Coins for each friend who participates in this event ( Up to 30 friends). One Tiger will be rewarded 1000 coins for the comments with the Most L","images":[{"img":"https://community-static.tradeup.com/news/9a6eadadb6cdfcfb17ccfa701ef66cb1","width":"900","height":"1200"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9011908737","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":142,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000431","authorId":"9000000000000431","name":"PandoraHaggai","avatar":"https://static.tigerbbs.com/1697f3f91fe5c84e7af6ee5dbdfb3d88","crmLevel":1,"crmLevelSwitch":0,"idStr":"9000000000000431","authorIdStr":"9000000000000431"},"content":"I don't understand people who starve to lose weight.","text":"I don't understand people who starve to lose weight.","html":"I don't understand people who starve to lose weight."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887779091,"gmtCreate":1632103020413,"gmtModify":1676530701062,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"Quite true, iPhone 13 didn’t surprise many ppl but it’s share price do show remarkable results to investorsPls comment and like. Thanks.&nbsp;","listText":"Quite true, iPhone 13 didn’t surprise many ppl but it’s share price do show remarkable results to investorsPls comment and like. Thanks.&nbsp;","text":"Quite true, iPhone 13 didn’t surprise many ppl but it’s share price do show remarkable results to investorsPls comment and like. Thanks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/887779091","repostId":"1170351753","repostType":4,"repost":{"id":"1170351753","pubTimestamp":1632097276,"share":"https://ttm.financial/m/news/1170351753?lang=&edition=fundamental","pubTime":"2021-09-20 08:21","market":"us","language":"en","title":"The iPhone 13 Didn’t Surprise. Apple’s Stock Still Might.","url":"https://stock-news.laohu8.com/highlight/detail?id=1170351753","media":"Barrons","summary":"On the surface, last week’s edition of Apple’s annual fall product launch event was kind of a yawner","content":"<p>On the surface, last week’s edition of Apple’s annual fall product launch event was kind of a yawner. There weren’t many surprises, the new iPhone 13 lineup was in line with expectations, and upgrades to iPads and the Apple Watch were less than revolutionary.</p>\n<p>But dig in a little, and you can find lots to chew on. The biggest takeaway is that Apple’s (ticker: AAPL) outlook is a little brighter than skeptics on the Street would have you believe.</p>\n<p></p>\n<p>No question, iPhone updates were incremental, mostly under-the-hood tweaks. The notch at the top of the screen is smaller, and the new A15 bionic processor at the core of the phone is faster than the iPhone 12’s A14 chip. There’s longer battery life, improved cameras, and higher memory capacity at comparable price points.</p>\n<p>A few analysts view the new option for one terabyte of flash memory storage on iPhone 13 Pro models as a big deal. While it’s not entirely clear to me who needs that much capacity, the trend towards higher average storage on phones is a good thing not only for Apple, but also for memory chip manufacturers&nbsp;Western Digital&nbsp; (WDC) and&nbsp;Micron Technology&nbsp;(MU). The base model phones now have twice the storage capacity as last year. The $799 iPhone 12 had 64 gigabytes of storage; this year, the same price comes with 128 GB. Last year, a phone with 256 GB would run $949; this year, you can have the same capacity for $899. If you want a top-of-the-line, 6.7-inch Pro Max with one terabyte of storage, it will set you back $1,599.</p>\n<p></p>\n<p>Bernstein analyst Toni Sacconaghi sees Apple’s pricing strategy as designed to continue a trend toward increasing iPhones’ average selling prices, or ASPs. He estimates that Apple is on track for an 18% year-over-year increase in ASPs for the September 2021 fiscal year. He reports that the iPhone ASP earlier this year reached more than $880, the highest since the phone was launched in 2008.</p>\n<p>Driving the trend is an apparent consumer preference—at least among iPhone 12 fanciers—for higher-end Pro and Pro Max models, which he argues carry margins 10 percentage points higher than non-Pro models. (Apple apparently generates huge margins on incremental memory.) Sacconaghi calculates that, if the iPhone sales mix on the new lineup is comparable to the iPhone 12’s, average selling prices would be up 5%.</p>\n<p>Morgan Stanley’s Katy Huberty is focused on both the profitability of the new phones—and affordability. She agrees that the big news might be Apple’s move to lift iPhone profits by driving up average prices, but notes that aggressive carrier promotions and trade-in deals increase affordability and should keep demand buoyant. Huberty notes that&nbsp;AT&amp;T&nbsp;(T) and&nbsp;Verizon&nbsp;(VZ) are offering more aggressive promotions for the iPhone 13 than they did for the 12, no doubt reflecting their need to flow traffic to 5G networks after spending billions to buy spectrum and build out faster infrastructures.</p>\n<p></p>\n<p>Jefferies analyst Kyle McNealy goes so far as to suggest that carrier promotions were the biggest news last week. AT&amp;T, Verizon, and&nbsp;T-Mobile US&nbsp;(TMUS) are all offering the base iPhone 13 model free to qualifying customers. AT&amp;T will give you a Pro for free. Trade in an iPhone 12 Pro Max at T-Mobile, and you can have a free iPhone 13 Pro Max. Apple wants to expand its user base, boost customer loyalty, and drive services growth. The carriers want to spur 5G. Consumers get better phones. It’s a win-win-win.</p>\n<p></p>\n<p>Huberty notes that only about 5% of the iPhone installed base is using 5G; she expects an “elongated” 5G adoption cycle that should keep demand for new phones high. “Should early reports indicate elevated iPhone demand versus low buy-side expectations, we’d expect Apple shares to outperform in the near-term,” she writes in a research note.</p>\n<p>One of the trickiest elements of the story for investors will be an inevitable slowing of Apple’s growth rate. Street estimates call for sales growth to tumble from 34% in fiscal 2021, to under 4% in fiscal 2022. But if iPhone demand holds up, aided by support from 5G carriers, sales gains could be higher. Loup Ventures co-founder Gene Munster, who followed Apple as an analyst, told me last week that he thinks growth will be closer to 10%. Keep in mind that in fiscal 2019 —prepandemic (and pre-5G)—Apple sales fell 2% from the prior year, with iPhone sales down 5%. Munster sees a path for the stock to get to $200 a share, a third higher than today.</p>\n<p><b>Aquick update:</b> As previewed here last week,Cisco Systems&nbsp;(CSCO) on Wednesday held its first analyst meeting in four years, to a muted reaction. Cisco sees both revenue and profit growth ranging from 5% to 7% a year through the July 2025 fiscal year, driven by 15% to 17% growth in its subscription businesses. Cisco also affirmed its policy to return at least 50% of free cash flow in dividends and buybacks.</p>\n<p></p>\n<p>But there were minor disappointments. Some investors had hoped for a more aggressive approach to buying back stock—and they were bummed that Cisco isn’t projecting operating leverage, with profits expected to grow in line with revenue. That reflects higher component costs due to shortages and a desire to invest in growth. Cisco CEO Chuck Robbins sees the company’s addressable market at $400 billion, with another $500 billion in businesses it doesn’t currently address. Don’t be surprised to see M&amp;A pick up.</p>\n<p>Bottom line: I repeat my view from last week. Cisco is cheap, and there’s a path to substantial gains.</p>\n<p></p>\n<p></p>\n<p></p>\n<p></p>\n<p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The iPhone 13 Didn’t Surprise. Apple’s Stock Still Might.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe iPhone 13 Didn’t Surprise. Apple’s Stock Still Might.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-20 08:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/iphone-13-apple-stock-51631898248?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On the surface, last week’s edition of Apple’s annual fall product launch event was kind of a yawner. There weren’t many surprises, the new iPhone 13 lineup was in line with expectations, and upgrades...</p>\n\n<a href=\"https://www.barrons.com/articles/iphone-13-apple-stock-51631898248?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.barrons.com/articles/iphone-13-apple-stock-51631898248?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170351753","content_text":"On the surface, last week’s edition of Apple’s annual fall product launch event was kind of a yawner. There weren’t many surprises, the new iPhone 13 lineup was in line with expectations, and upgrades to iPads and the Apple Watch were less than revolutionary.\nBut dig in a little, and you can find lots to chew on. The biggest takeaway is that Apple’s (ticker: AAPL) outlook is a little brighter than skeptics on the Street would have you believe.\n\nNo question, iPhone updates were incremental, mostly under-the-hood tweaks. The notch at the top of the screen is smaller, and the new A15 bionic processor at the core of the phone is faster than the iPhone 12’s A14 chip. There’s longer battery life, improved cameras, and higher memory capacity at comparable price points.\nA few analysts view the new option for one terabyte of flash memory storage on iPhone 13 Pro models as a big deal. While it’s not entirely clear to me who needs that much capacity, the trend towards higher average storage on phones is a good thing not only for Apple, but also for memory chip manufacturers Western Digital  (WDC) and Micron Technology (MU). The base model phones now have twice the storage capacity as last year. The $799 iPhone 12 had 64 gigabytes of storage; this year, the same price comes with 128 GB. Last year, a phone with 256 GB would run $949; this year, you can have the same capacity for $899. If you want a top-of-the-line, 6.7-inch Pro Max with one terabyte of storage, it will set you back $1,599.\n\nBernstein analyst Toni Sacconaghi sees Apple’s pricing strategy as designed to continue a trend toward increasing iPhones’ average selling prices, or ASPs. He estimates that Apple is on track for an 18% year-over-year increase in ASPs for the September 2021 fiscal year. He reports that the iPhone ASP earlier this year reached more than $880, the highest since the phone was launched in 2008.\nDriving the trend is an apparent consumer preference—at least among iPhone 12 fanciers—for higher-end Pro and Pro Max models, which he argues carry margins 10 percentage points higher than non-Pro models. (Apple apparently generates huge margins on incremental memory.) Sacconaghi calculates that, if the iPhone sales mix on the new lineup is comparable to the iPhone 12’s, average selling prices would be up 5%.\nMorgan Stanley’s Katy Huberty is focused on both the profitability of the new phones—and affordability. She agrees that the big news might be Apple’s move to lift iPhone profits by driving up average prices, but notes that aggressive carrier promotions and trade-in deals increase affordability and should keep demand buoyant. Huberty notes that AT&T (T) and Verizon (VZ) are offering more aggressive promotions for the iPhone 13 than they did for the 12, no doubt reflecting their need to flow traffic to 5G networks after spending billions to buy spectrum and build out faster infrastructures.\n\nJefferies analyst Kyle McNealy goes so far as to suggest that carrier promotions were the biggest news last week. AT&T, Verizon, and T-Mobile US (TMUS) are all offering the base iPhone 13 model free to qualifying customers. AT&T will give you a Pro for free. Trade in an iPhone 12 Pro Max at T-Mobile, and you can have a free iPhone 13 Pro Max. Apple wants to expand its user base, boost customer loyalty, and drive services growth. The carriers want to spur 5G. Consumers get better phones. It’s a win-win-win.\n\nHuberty notes that only about 5% of the iPhone installed base is using 5G; she expects an “elongated” 5G adoption cycle that should keep demand for new phones high. “Should early reports indicate elevated iPhone demand versus low buy-side expectations, we’d expect Apple shares to outperform in the near-term,” she writes in a research note.\nOne of the trickiest elements of the story for investors will be an inevitable slowing of Apple’s growth rate. Street estimates call for sales growth to tumble from 34% in fiscal 2021, to under 4% in fiscal 2022. But if iPhone demand holds up, aided by support from 5G carriers, sales gains could be higher. Loup Ventures co-founder Gene Munster, who followed Apple as an analyst, told me last week that he thinks growth will be closer to 10%. Keep in mind that in fiscal 2019 —prepandemic (and pre-5G)—Apple sales fell 2% from the prior year, with iPhone sales down 5%. Munster sees a path for the stock to get to $200 a share, a third higher than today.\nAquick update: As previewed here last week,Cisco Systems (CSCO) on Wednesday held its first analyst meeting in four years, to a muted reaction. Cisco sees both revenue and profit growth ranging from 5% to 7% a year through the July 2025 fiscal year, driven by 15% to 17% growth in its subscription businesses. Cisco also affirmed its policy to return at least 50% of free cash flow in dividends and buybacks.\n\nBut there were minor disappointments. Some investors had hoped for a more aggressive approach to buying back stock—and they were bummed that Cisco isn’t projecting operating leverage, with profits expected to grow in line with revenue. That reflects higher component costs due to shortages and a desire to invest in growth. Cisco CEO Chuck Robbins sees the company’s addressable market at $400 billion, with another $500 billion in businesses it doesn’t currently address. Don’t be surprised to see M&A pick up.\nBottom line: I repeat my view from last week. Cisco is cheap, and there’s a path to substantial gains.","news_type":1},"isVote":1,"tweetType":1,"viewCount":103,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887953732,"gmtCreate":1631962996526,"gmtModify":1676530679181,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"Looks like most countries will go for the 3rddose of covid&nbsp;vaccination soon ….Pls comment and like. Thanks.&nbsp;","listText":"Looks like most countries will go for the 3rddose of covid&nbsp;vaccination soon ….Pls comment and like. Thanks.&nbsp;","text":"Looks like most countries will go for the 3rddose of covid vaccination soon ….Pls comment and like. Thanks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/887953732","repostId":"2168957763","repostType":4,"repost":{"id":"2168957763","pubTimestamp":1631950800,"share":"https://ttm.financial/m/news/2168957763?lang=&edition=fundamental","pubTime":"2021-09-18 15:40","market":"us","language":"en","title":"FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations","url":"https://stock-news.laohu8.com/highlight/detail?id=2168957763","media":"StreetInsider","summary":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization ti","content":"<ul>\n <li><i>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants </i></li>\n <li><i>Reactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series</i></li>\n <li><i>Real-world data presented by Israel Ministry of Health show additional protection after receiving a</i> <i>booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine</i> <i>rollout</i></li>\n <li><i>FDA expected to make its decision in the coming days </i></li>\n</ul>\n<p><b>NEW YORK AND MAINZ, GERMANY, September 17, 2021</b>—Pfizer Inc. (NYSE: PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.</p>\n<p>VRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.</p>\n<p>At this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.</p>\n<p>The FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.</p>\n<p>“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said <b>Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research &amp; Development, Pfizer</b>. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”</p>\n<p>“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said <b>Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.</b></p>\n<p>VRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.</p>\n<p>Real-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in <i>The New England Journal of Medicine</i>. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.</p>\n<p>Under the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was <u>previously authorized</u> for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.</p>\n<p>COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.</p>\n<p><b>U.S. Indication &amp; Authorized Use</b>COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.</p>\n<ul>\n <li>It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older</li>\n <li>It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:</li>\n</ul>\n<p>The Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:</p>\n<ul>\n <li>prevent COVID-19 in individuals 12 years of age and older, and</li>\n <li>provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise</li>\n</ul>\n<p>The FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.</p>\n<p><b>EUA Statement</b>This emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&amp;C Act unless the declaration is terminated or authorization revoked sooner.</p>\n<p><b>Important Safety Information</b>Individuals should <b>not</b> get the Pfizer-BioNTech COVID-19 Vaccine if they:</p>\n<ul>\n <li>had a severe allergic reaction after a previous dose of this vaccine</li>\n <li>had a severe allergic reaction to any ingredient of this vaccine</li>\n</ul>\n<p>Individuals should tell the vaccination provider about all of their medical conditions, including if they:</p>\n<ul>\n <li>have any allergies</li>\n <li>have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)</li>\n <li>have a fever</li>\n <li>have a bleeding disorder or are on a blood thinner</li>\n <li>are immunocompromised or are on a medicine that affects the immune system</li>\n <li>are pregnant, plan to become pregnant, or are breastfeeding</li>\n <li>have received another COVID-19 vaccine</li>\n <li>have ever fainted in association with an injection</li>\n</ul>\n<p>The vaccine may not protect everyone.</p>\n<p>Side effects reported with the vaccine include:</p>\n<ul>\n <li>There is a remote chance that the vaccine could cause a severe allergic reaction</li>\n <li>Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:</li>\n <li>Side effects that have been reported with the vaccine include:</li>\n <li>These may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away</li>\n</ul>\n<p>There is no information on the use of the vaccine with other vaccines.</p>\n<p>Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit <u>http://www.vaers.hhs.gov</u> or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at <u>www.pfizersafetyreporting.com</u> or by calling 1-800-438-1985.</p>\n<p>Please <u>click here</u> for full Prescribing Information (16+ years of age). Please <u>click here</u> for Fact Sheet for Vaccination Providers (12+ years of age).</p>\n<p><b>About Pfizer: Breakthroughs That Change Patients’ Lives</b>At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at <u>www.Pfizer.com</u>. In addition, to learn more, please visit us on <u>www.Pfizer.com</u> and follow us on <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> at <u>@Pfizer</u> and <u>@Pfizer News</u>, <u>LinkedIn</u>, <u>YouTube</u> and like us on <a href=\"https://laohu8.com/S/FB\">Facebook</a> at <u>Facebook.com/Pfizer</u>.</p>\n<p><b>Pfizer Disclosure Notice</b>The information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</p>\n<p>This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.</p>\n<p>A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at <u>www.sec.gov</u> and <u>www.pfizer.com</u>.</p>\n<p><b>About BioNTech</b>Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit <u>www.BioNTech.de</u>.</p>\n<p><b>BioNTech Forward-looking Statements</b>This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.</p>\n<p>For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at <u>www.sec.gov</u>. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 15:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18955632><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18955632\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18955632","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2168957763","content_text":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series\nReal-world data presented by Israel Ministry of Health show additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout\nFDA expected to make its decision in the coming days \n\nNEW YORK AND MAINZ, GERMANY, September 17, 2021—Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.\nVRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.\nAt this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.\nThe FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.\n“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”\n“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.\nVRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.\nReal-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in The New England Journal of Medicine. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.\nUnder the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was previously authorized for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.\nCOMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.\nU.S. Indication & Authorized UseCOMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.\n\nIt is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older\nIt is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:\n\nThe Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:\n\nprevent COVID-19 in individuals 12 years of age and older, and\nprovide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise\n\nThe FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.\nEUA StatementThis emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.\nImportant Safety InformationIndividuals should not get the Pfizer-BioNTech COVID-19 Vaccine if they:\n\nhad a severe allergic reaction after a previous dose of this vaccine\nhad a severe allergic reaction to any ingredient of this vaccine\n\nIndividuals should tell the vaccination provider about all of their medical conditions, including if they:\n\nhave any allergies\nhave had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)\nhave a fever\nhave a bleeding disorder or are on a blood thinner\nare immunocompromised or are on a medicine that affects the immune system\nare pregnant, plan to become pregnant, or are breastfeeding\nhave received another COVID-19 vaccine\nhave ever fainted in association with an injection\n\nThe vaccine may not protect everyone.\nSide effects reported with the vaccine include:\n\nThere is a remote chance that the vaccine could cause a severe allergic reaction\nMyocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:\nSide effects that have been reported with the vaccine include:\nThese may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away\n\nThere is no information on the use of the vaccine with other vaccines.\nPatients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985.\nPlease click here for full Prescribing Information (16+ years of age). Please click here for Fact Sheet for Vaccination Providers (12+ years of age).\nAbout Pfizer: Breakthroughs That Change Patients’ LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.\nPfizer Disclosure NoticeThe information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.\nThis release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.\nA further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.\nAbout BioNTechBiopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.\nBioNTech Forward-looking StatementsThis press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.\nFor a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.","news_type":1},"isVote":1,"tweetType":1,"viewCount":147,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3581999478634265","authorId":"3581999478634265","name":"woonws","avatar":"https://static.tigerbbs.com/f26ed1a10ee84ab97229aad191ef3133","crmLevel":2,"crmLevelSwitch":0,"idStr":"3581999478634265","authorIdStr":"3581999478634265"},"content":"True! As the science becomes more certain","text":"True! As the science becomes more certain","html":"True! As the science becomes more certain"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":811993992,"gmtCreate":1630282169317,"gmtModify":1676530254913,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"Who will be&nbsp;the next CEO after Tim Cook to lead Apple&nbsp;?Pls like and comment. Thanks.&nbsp;","listText":"Who will be&nbsp;the next CEO after Tim Cook to lead Apple&nbsp;?Pls like and comment. Thanks.&nbsp;","text":"Who will be the next CEO after Tim Cook to lead Apple ?Pls like and comment. Thanks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/811993992","repostId":"1164294381","repostType":4,"repost":{"id":"1164294381","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1630281347,"share":"https://ttm.financial/m/news/1164294381?lang=&edition=fundamental","pubTime":"2021-08-30 07:55","market":"us","language":"en","title":"Here Is What Apple CEO Tim Cook Plans To Do Before Stepping Down","url":"https://stock-news.laohu8.com/highlight/detail?id=1164294381","media":"Benzinga","summary":"Apple Inc AAPL 0.72%CEO Tim Cook has been leading the tech giant for the last ten years, and a repor","content":"<p><b>Apple Inc</b>&nbsp;AAPL 0.72%CEO&nbsp;<b>Tim Cook</b>&nbsp;has been leading the tech giant for the last ten years, and a report suggests&nbsp;he \"probably\" won't be with&nbsp;the company in another ten years' time.</p>\n<p><b>What Happened:</b>The&nbsp;Apple Insider&nbsp;has reported, quoting Bloomberg's Mark Gurman's \"Power On\" newsletter, that Apple employees think Cook will stay around for one more major new product category before stepping down as CEO.</p>\n<p>\"The belief inside Apple is that Cook just wants to stick around for one more major new product category, which is likely to be&nbsp;<b>Augmented Reality Glasses</b>&nbsp;rather than a car — something that's even further out,\" writes Gurman.</p>\n<p>In December 2020,&nbsp;Reuters reported&nbsp;Apple is aiming to launch an autonomous electric vehicle in 2024.</p>\n<p>\"He also understands that running a Silicon Valley company is typically a young person's game, and he's not going to stay far beyond his prime,\" Gurman added.</p>\n<p>In April, when&nbsp;asked&nbsp;about staying with Apple for a decade, Cook said, \"Ten more years? Probably not. But I can tell you that I feel great right now and the date is not in sight. But ten more years is a long time — and probably not ten more years.\"</p>\n<p>Gurman speculates that Cook will retire sometime between 2025 and 2028. He added that Cook's pay deal would also expire in 2025.</p>\n<p><b>Why It Matters:</b>Just ten years ago,Tim Cook&nbsp;took over as CEO of Apple for iconic visionary Apple co-founder&nbsp;<b>Steve Jobs.</b>&nbsp;At&nbsp;Jobs' departure, some investors and analysts were skeptical of Cook's ability to fill Jobs' shoes.</p>\n<p>Apple integrated its popular voice assistant Siri into the iPhone 4S in 2011. In 2014, Apple unveiled the Apple Watch. In 2015, it launched the streaming service Apple Music. The iPhone X in 2017 came with facial recognition software, a 3D camera, and wireless charging capabilities.</p>\n<p>In 2019, Apple launched the streaming video service Apple TV+.&nbsp;Apple has also been working on its secret \"Project Titan\" auto project at an undisclosed location since 2014.</p>\n<p>Apple shares have generated a total return of roughly 1,210% in the past decade.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here Is What Apple CEO Tim Cook Plans To Do Before Stepping Down</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere Is What Apple CEO Tim Cook Plans To Do Before Stepping Down\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-30 07:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Apple Inc</b>&nbsp;AAPL 0.72%CEO&nbsp;<b>Tim Cook</b>&nbsp;has been leading the tech giant for the last ten years, and a report suggests&nbsp;he \"probably\" won't be with&nbsp;the company in another ten years' time.</p>\n<p><b>What Happened:</b>The&nbsp;Apple Insider&nbsp;has reported, quoting Bloomberg's Mark Gurman's \"Power On\" newsletter, that Apple employees think Cook will stay around for one more major new product category before stepping down as CEO.</p>\n<p>\"The belief inside Apple is that Cook just wants to stick around for one more major new product category, which is likely to be&nbsp;<b>Augmented Reality Glasses</b>&nbsp;rather than a car — something that's even further out,\" writes Gurman.</p>\n<p>In December 2020,&nbsp;Reuters reported&nbsp;Apple is aiming to launch an autonomous electric vehicle in 2024.</p>\n<p>\"He also understands that running a Silicon Valley company is typically a young person's game, and he's not going to stay far beyond his prime,\" Gurman added.</p>\n<p>In April, when&nbsp;asked&nbsp;about staying with Apple for a decade, Cook said, \"Ten more years? Probably not. But I can tell you that I feel great right now and the date is not in sight. But ten more years is a long time — and probably not ten more years.\"</p>\n<p>Gurman speculates that Cook will retire sometime between 2025 and 2028. He added that Cook's pay deal would also expire in 2025.</p>\n<p><b>Why It Matters:</b>Just ten years ago,Tim Cook&nbsp;took over as CEO of Apple for iconic visionary Apple co-founder&nbsp;<b>Steve Jobs.</b>&nbsp;At&nbsp;Jobs' departure, some investors and analysts were skeptical of Cook's ability to fill Jobs' shoes.</p>\n<p>Apple integrated its popular voice assistant Siri into the iPhone 4S in 2011. In 2014, Apple unveiled the Apple Watch. In 2015, it launched the streaming service Apple Music. The iPhone X in 2017 came with facial recognition software, a 3D camera, and wireless charging capabilities.</p>\n<p>In 2019, Apple launched the streaming video service Apple TV+.&nbsp;Apple has also been working on its secret \"Project Titan\" auto project at an undisclosed location since 2014.</p>\n<p>Apple shares have generated a total return of roughly 1,210% in the past decade.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164294381","content_text":"Apple Inc AAPL 0.72%CEO Tim Cook has been leading the tech giant for the last ten years, and a report suggests he \"probably\" won't be with the company in another ten years' time.\nWhat Happened:The Apple Insider has reported, quoting Bloomberg's Mark Gurman's \"Power On\" newsletter, that Apple employees think Cook will stay around for one more major new product category before stepping down as CEO.\n\"The belief inside Apple is that Cook just wants to stick around for one more major new product category, which is likely to be Augmented Reality Glasses rather than a car — something that's even further out,\" writes Gurman.\nIn December 2020, Reuters reported Apple is aiming to launch an autonomous electric vehicle in 2024.\n\"He also understands that running a Silicon Valley company is typically a young person's game, and he's not going to stay far beyond his prime,\" Gurman added.\nIn April, when asked about staying with Apple for a decade, Cook said, \"Ten more years? Probably not. But I can tell you that I feel great right now and the date is not in sight. But ten more years is a long time — and probably not ten more years.\"\nGurman speculates that Cook will retire sometime between 2025 and 2028. He added that Cook's pay deal would also expire in 2025.\nWhy It Matters:Just ten years ago,Tim Cook took over as CEO of Apple for iconic visionary Apple co-founder Steve Jobs. At Jobs' departure, some investors and analysts were skeptical of Cook's ability to fill Jobs' shoes.\nApple integrated its popular voice assistant Siri into the iPhone 4S in 2011. In 2014, Apple unveiled the Apple Watch. In 2015, it launched the streaming service Apple Music. The iPhone X in 2017 came with facial recognition software, a 3D camera, and wireless charging capabilities.\nIn 2019, Apple launched the streaming video service Apple TV+. Apple has also been working on its secret \"Project Titan\" auto project at an undisclosed location since 2014.\nApple shares have generated a total return of roughly 1,210% in the past decade.","news_type":1},"isVote":1,"tweetType":1,"viewCount":273,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3578631759891221","authorId":"3578631759891221","name":"keaty","avatar":"https://static.tigerbbs.com/bcf9d00e41b755619a4b4c3eb6f05541","crmLevel":6,"crmLevelSwitch":0,"idStr":"3578631759891221","authorIdStr":"3578631759891221"},"content":"well, that another junction. hope get new good ceo else... ?. GE was once around 600 bil just one wrong ceo, become crippled. now in recovery. hv to be v. careful","text":"well, that another junction. hope get new good ceo else... ?. GE was once around 600 bil just one wrong ceo, become crippled. now in recovery. hv to be v. careful","html":"well, that another junction. hope get new good ceo else... ?. GE was once around 600 bil just one wrong ceo, become crippled. now in recovery. hv to be v. careful"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9094448744,"gmtCreate":1645228926889,"gmtModify":1676534010275,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"More vaccine&nbsp;choices and options for ppl to choose now ....","listText":"More vaccine&nbsp;choices and options for ppl to choose now ....","text":"More vaccine choices and options for ppl to choose now ....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094448744","repostId":"1167998825","repostType":4,"repost":{"id":"1167998825","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1645227126,"share":"https://ttm.financial/m/news/1167998825?lang=&edition=fundamental","pubTime":"2022-02-19 07:32","market":"us","language":"en","title":"Ocugen Says U.S. FDA Lifts Clinical Hold on IND Application for Covid Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1167998825","media":"Tiger Newspress","summary":"Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, deve","content":"<html><head></head><body><p>Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced that the U.S. Food and Drug Administration (FDA) has lifted its clinical hold on the Company’s Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152, known as COVAXIN™ outside the United States.</p><p>Ocugen shares soared about 34% in extended trading Friday.</p><p><img src=\"https://static.tigerbbs.com/aa4f293b5515029af37c7711bfa5927e\" tg-width=\"841\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>COVAXIN™ is a whole-virion inactivated COVID-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades.</p><p>“We are pleased to be able to move our clinical program for COVAXIN™ forward, which we hope will bring us closer to offering an alternative COVID-19 vaccine,” said Dr. Shankar Musunuri, Chairman of the Board, Chief Executive Officer, and Co-Founder of Ocugen. “We firmly believe that managing this pandemic requires more than one approach to vaccines, so we are heartened to be able to continue developing our vaccine candidate.”</p><p><b>About COVAXIN™ (BBV152)</b></p><p>COVAXIN™ (BBVI52) is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV). COVAXIN™ is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.</p><p>With more than 200 million doses having been administered to adults outside the U.S., COVAXIN™ is currently authorized under emergency use in 20 countries, and applications for emergency use authorization are pending in more than 60 other countries. The World Health Organization (WHO) recently added COVAXIN™ to its list of vaccines authorized for emergency use. And, as many as 110 countries have agreed to mutual recognition of COVID-19 vaccination certificates with India that includes vaccination using COVAXIN™. The trade name COVAXIN™ has not been evaluated by the FDA.</p><p><b>About Ocugen, Inc.</b></p><p>Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. and Canadian markets.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Says U.S. FDA Lifts Clinical Hold on IND Application for Covid Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Says U.S. FDA Lifts Clinical Hold on IND Application for Covid Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-02-19 07:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced that the U.S. Food and Drug Administration (FDA) has lifted its clinical hold on the Company’s Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152, known as COVAXIN™ outside the United States.</p><p>Ocugen shares soared about 34% in extended trading Friday.</p><p><img src=\"https://static.tigerbbs.com/aa4f293b5515029af37c7711bfa5927e\" tg-width=\"841\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p><p>COVAXIN™ is a whole-virion inactivated COVID-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades.</p><p>“We are pleased to be able to move our clinical program for COVAXIN™ forward, which we hope will bring us closer to offering an alternative COVID-19 vaccine,” said Dr. Shankar Musunuri, Chairman of the Board, Chief Executive Officer, and Co-Founder of Ocugen. “We firmly believe that managing this pandemic requires more than one approach to vaccines, so we are heartened to be able to continue developing our vaccine candidate.”</p><p><b>About COVAXIN™ (BBV152)</b></p><p>COVAXIN™ (BBVI52) is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV). COVAXIN™ is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.</p><p>With more than 200 million doses having been administered to adults outside the U.S., COVAXIN™ is currently authorized under emergency use in 20 countries, and applications for emergency use authorization are pending in more than 60 other countries. The World Health Organization (WHO) recently added COVAXIN™ to its list of vaccines authorized for emergency use. And, as many as 110 countries have agreed to mutual recognition of COVID-19 vaccination certificates with India that includes vaccination using COVAXIN™. The trade name COVAXIN™ has not been evaluated by the FDA.</p><p><b>About Ocugen, Inc.</b></p><p>Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. and Canadian markets.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167998825","content_text":"Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced that the U.S. Food and Drug Administration (FDA) has lifted its clinical hold on the Company’s Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152, known as COVAXIN™ outside the United States.Ocugen shares soared about 34% in extended trading Friday.COVAXIN™ is a whole-virion inactivated COVID-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades.“We are pleased to be able to move our clinical program for COVAXIN™ forward, which we hope will bring us closer to offering an alternative COVID-19 vaccine,” said Dr. Shankar Musunuri, Chairman of the Board, Chief Executive Officer, and Co-Founder of Ocugen. “We firmly believe that managing this pandemic requires more than one approach to vaccines, so we are heartened to be able to continue developing our vaccine candidate.”About COVAXIN™ (BBV152)COVAXIN™ (BBVI52) is an investigational vaccine candidate product in the U.S. It was developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV). COVAXIN™ is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.With more than 200 million doses having been administered to adults outside the U.S., COVAXIN™ is currently authorized under emergency use in 20 countries, and applications for emergency use authorization are pending in more than 60 other countries. The World Health Organization (WHO) recently added COVAXIN™ to its list of vaccines authorized for emergency use. And, as many as 110 countries have agreed to mutual recognition of COVID-19 vaccination certificates with India that includes vaccination using COVAXIN™. The trade name COVAXIN™ has not been evaluated by the FDA.About Ocugen, Inc.Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. and Canadian markets.","news_type":1},"isVote":1,"tweetType":1,"viewCount":528,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9092425077,"gmtCreate":1644716614905,"gmtModify":1676533955264,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"Yes, a innovative and potential company ....","listText":"Yes, a innovative and potential company ....","text":"Yes, a innovative and potential company ....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092425077","repostId":"2210752103","repostType":4,"repost":{"id":"2210752103","pubTimestamp":1644714900,"share":"https://ttm.financial/m/news/2210752103?lang=&edition=fundamental","pubTime":"2022-02-13 09:15","market":"us","language":"en","title":"This Disruptive Company Has Explosive Growth Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2210752103","media":"Motley Fool","summary":"The company's latest innovation transforms how companies perform a routine task.","content":"<html><head></head><body><p><b>Paycom Software</b> (NYSE:PAYC) has been at the forefront of disrupting the payroll sector since CEO Chad Richison founded the company in 1998. His company revolutionized the payroll process by taking it entirely online. It has continued to be a disruptive force over the years, developing a single cloud-based software solution to help companies manage all their human resources (HR) processes.</p><p>The company&#39;s latest innovation, Beti, is once again disrupting the industry by changing the entire payroll procedure. It&#39;s helping drive explosive growth for Paycom, which could continue for years to come.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/933b605f0da9ea748d7fd549f8360a85\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/><span>Image source: Getty Images.</span></p><h2>A better payroll system</h2><p>Richison discussed Paycom&#39;s latest disruptive move on the fourth-quarter conference call. He noted that the company &#34;extended our platform to the employee even further through innovations like BETI, which enables employees to do their own payroll, and we are seeing very strong adoption and record employee usage.&#34;</p><p>The company sees Beti, which stands for Better Employee Transaction Interface, as the new way of doing payroll. The industry-first employee-driven payroll solution improves data accuracy, oversight, and user experience. It puts the payroll responsibility into the hands of employees, eliminating a multistep, imperfect, and time-consuming process for HR departments while giving employees more insight into their pay.</p><p>Richison stated on the call:</p><blockquote>For years, I have been predicting the end of the old model, whereby HR and payroll personnel&#39;s routine of inputting data for employees, is replaced by a self-service model that provides employees direct access to the database. The old model is dying and that is good for both the business and the employee. Paycom is leading this transformation.</blockquote><p>That&#39;s just the latest innovation from the company. The company&#39;s single-database HR platform works better than the cobbled-together systems that most companies use today. That has enabled Paycom to capitalize by offering companies an easy-to-use system that improves user experiences, allowing them to maximize the return on this investment in Paycom&#39;s software.</p><h2>An unstoppable growth driver</h2><p>This award-winning solution has been a smashing success. It helped drive record annual revenue retention of 94% in 2021, up from 93% in the prior year. It was also a key growth driver. The company ended the year with nearly 34,000 clients, up 9% compared to 2020. Meanwhile, revenue surged 29% year-over-year in the fourth quarter and 25.4% for the full year. Earnings grew even faster as its margin expanded despite aggressive spending to grow the business. The company delivered an adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) margin of 39.7% of its revenue in 2021, up from 39.3% in 2020.</p><p>Paycom is only scratching the surface of its potential. Richison noted on the call that &#34;we still only have approximately 5% of the TAM (total available market) today, so there&#39;s plenty of runway ahead to expand and continue to capture market share.&#34; It&#39;s investing heavily to continue taking more market share. It opened five new outside sales offices over the last five months (<a href=\"https://laohu8.com/S/MHC.AU\">Manhattan</a>, Las Vegas, Jacksonville, New England, and South Jersey) -- bringing the total to 54 -- to expand its geographic reach. In addition, it has expanded the upper end of its target client size from those with up to 5,000 employees to those with upwards of 10,000 employees.</p><p>These catalysts have Paycom positioned to continue growing fast in 2022 and beyond. The cloud-based software company sees its revenue rising to more than $1.3 billion this year, putting it up nearly 25% from last year&#39;s total. Meanwhile, it sees a further improvement in its adjusted EBITDA margin to around 40% this year, suggesting continued strong profit growth.</p><h2>Lots of growth still ahead</h2><p>Paycom continues to disrupt the payroll industry by launching innovative software solutions that improve the process. While it has grown tremendously over the years, it still has lots of room to run. That upside potential makes it a stock that investors won&#39;t want to miss.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Disruptive Company Has Explosive Growth Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Disruptive Company Has Explosive Growth Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-13 09:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/12/this-disruptive-company-has-explosive-growth-poten/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Paycom Software (NYSE:PAYC) has been at the forefront of disrupting the payroll sector since CEO Chad Richison founded the company in 1998. His company revolutionized the payroll process by taking it ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/12/this-disruptive-company-has-explosive-growth-poten/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PAYC":"Paycom Software, Inc.","BK4023":"应用软件","BK4528":"SaaS概念","BK4203":"医疗保健房地产投资信托"},"source_url":"https://www.fool.com/investing/2022/02/12/this-disruptive-company-has-explosive-growth-poten/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2210752103","content_text":"Paycom Software (NYSE:PAYC) has been at the forefront of disrupting the payroll sector since CEO Chad Richison founded the company in 1998. His company revolutionized the payroll process by taking it entirely online. It has continued to be a disruptive force over the years, developing a single cloud-based software solution to help companies manage all their human resources (HR) processes.The company's latest innovation, Beti, is once again disrupting the industry by changing the entire payroll procedure. It's helping drive explosive growth for Paycom, which could continue for years to come.Image source: Getty Images.A better payroll systemRichison discussed Paycom's latest disruptive move on the fourth-quarter conference call. He noted that the company \"extended our platform to the employee even further through innovations like BETI, which enables employees to do their own payroll, and we are seeing very strong adoption and record employee usage.\"The company sees Beti, which stands for Better Employee Transaction Interface, as the new way of doing payroll. The industry-first employee-driven payroll solution improves data accuracy, oversight, and user experience. It puts the payroll responsibility into the hands of employees, eliminating a multistep, imperfect, and time-consuming process for HR departments while giving employees more insight into their pay.Richison stated on the call:For years, I have been predicting the end of the old model, whereby HR and payroll personnel's routine of inputting data for employees, is replaced by a self-service model that provides employees direct access to the database. The old model is dying and that is good for both the business and the employee. Paycom is leading this transformation.That's just the latest innovation from the company. The company's single-database HR platform works better than the cobbled-together systems that most companies use today. That has enabled Paycom to capitalize by offering companies an easy-to-use system that improves user experiences, allowing them to maximize the return on this investment in Paycom's software.An unstoppable growth driverThis award-winning solution has been a smashing success. It helped drive record annual revenue retention of 94% in 2021, up from 93% in the prior year. It was also a key growth driver. The company ended the year with nearly 34,000 clients, up 9% compared to 2020. Meanwhile, revenue surged 29% year-over-year in the fourth quarter and 25.4% for the full year. Earnings grew even faster as its margin expanded despite aggressive spending to grow the business. The company delivered an adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) margin of 39.7% of its revenue in 2021, up from 39.3% in 2020.Paycom is only scratching the surface of its potential. Richison noted on the call that \"we still only have approximately 5% of the TAM (total available market) today, so there's plenty of runway ahead to expand and continue to capture market share.\" It's investing heavily to continue taking more market share. It opened five new outside sales offices over the last five months (Manhattan, Las Vegas, Jacksonville, New England, and South Jersey) -- bringing the total to 54 -- to expand its geographic reach. In addition, it has expanded the upper end of its target client size from those with up to 5,000 employees to those with upwards of 10,000 employees.These catalysts have Paycom positioned to continue growing fast in 2022 and beyond. The cloud-based software company sees its revenue rising to more than $1.3 billion this year, putting it up nearly 25% from last year's total. Meanwhile, it sees a further improvement in its adjusted EBITDA margin to around 40% this year, suggesting continued strong profit growth.Lots of growth still aheadPaycom continues to disrupt the payroll industry by launching innovative software solutions that improve the process. While it has grown tremendously over the years, it still has lots of room to run. That upside potential makes it a stock that investors won't want to miss.","news_type":1},"isVote":1,"tweetType":1,"viewCount":262,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887156826,"gmtCreate":1632011224365,"gmtModify":1676530685072,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"Looks like COVID has&nbsp;help many healthcare and tech&nbsp;companies to become popular&nbsp;or in demand …Pls comment and like. Thanks.&nbsp;","listText":"Looks like COVID has&nbsp;help many healthcare and tech&nbsp;companies to become popular&nbsp;or in demand …Pls comment and like. Thanks.&nbsp;","text":"Looks like COVID has help many healthcare and tech companies to become popular or in demand …Pls comment and like. Thanks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/887156826","repostId":"2168573380","repostType":4,"isVote":1,"tweetType":1,"viewCount":149,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4087829320241190","authorId":"4087829320241190","name":"CYKuan","avatar":"https://community-static.tradeup.com/news/a600e1308bcb427dcbe9716594333839","crmLevel":5,"crmLevelSwitch":1,"idStr":"4087829320241190","authorIdStr":"4087829320241190"},"content":"Crisis is a turning point","text":"Crisis is a turning point","html":"Crisis is a turning point"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9038169691,"gmtCreate":1646778312852,"gmtModify":1676534159949,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$</a>price gonna go up ....???","listText":"<a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$</a>price gonna go up ....???","text":"$Tesla Motors(TSLA)$price gonna go up ....???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9038169691","repostId":"1134638354","repostType":4,"repost":{"id":"1134638354","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1646751312,"share":"https://ttm.financial/m/news/1134638354?lang=&edition=fundamental","pubTime":"2022-03-08 22:55","market":"fut","language":"en","title":"Nickel ETN Tumbled 14% After London Metals Exchange Cancels All Nickel Trades","url":"https://stock-news.laohu8.com/highlight/detail?id=1134638354","media":"Tiger Newspress","summary":"Nickel ETN tumbled 14% after London Metals Exchange cancels all nickel trades.The London Metals Exchange said it cancelled all nickel trades, after the contract surged as much as 111% before a trading halt. The cancellation applies to all trades made after midnight U.K. time on Tuesday. The LME said the trading was due to the situation in Russia and Ukraine, as well as the low-stock environment and high pricing volatility, as it said \"current events are unprecedented\" and that it was working to ","content":"<html><head></head><body><p>Nickel ETN tumbled 14% after London Metals Exchange cancels all nickel trades.<img src=\"https://static.tigerbbs.com/8fa56afcddbd1703e28553834deaedc5\" tg-width=\"1146\" tg-height=\"915\" referrerpolicy=\"no-referrer\"/>The London Metals Exchange said it cancelled all nickel trades, after the contract surged as much as 111% before a trading halt. </p><p>The cancellation applies to all trades made after midnight U.K. time on Tuesday. </p><p>The LME said the trading was due to the situation in Russia and Ukraine, as well as the low-stock environment and high pricing volatility, as it said &#34;current events are unprecedented&#34; and that it was working to ensure the orderly functioning of the market.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nickel ETN Tumbled 14% After London Metals Exchange Cancels All Nickel Trades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNickel ETN Tumbled 14% After London Metals Exchange Cancels All Nickel Trades\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-03-08 22:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Nickel ETN tumbled 14% after London Metals Exchange cancels all nickel trades.<img src=\"https://static.tigerbbs.com/8fa56afcddbd1703e28553834deaedc5\" tg-width=\"1146\" tg-height=\"915\" referrerpolicy=\"no-referrer\"/>The London Metals Exchange said it cancelled all nickel trades, after the contract surged as much as 111% before a trading halt. </p><p>The cancellation applies to all trades made after midnight U.K. time on Tuesday. </p><p>The LME said the trading was due to the situation in Russia and Ukraine, as well as the low-stock environment and high pricing volatility, as it said &#34;current events are unprecedented&#34; and that it was working to ensure the orderly functioning of the market.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JJN":"镍ETN-iPath","NICK.UK":"镍ETF"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134638354","content_text":"Nickel ETN tumbled 14% after London Metals Exchange cancels all nickel trades.The London Metals Exchange said it cancelled all nickel trades, after the contract surged as much as 111% before a trading halt. The cancellation applies to all trades made after midnight U.K. time on Tuesday. The LME said the trading was due to the situation in Russia and Ukraine, as well as the low-stock environment and high pricing volatility, as it said \"current events are unprecedented\" and that it was working to ensure the orderly functioning of the market.","news_type":1},"isVote":1,"tweetType":1,"viewCount":141,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803884988,"gmtCreate":1627432169244,"gmtModify":1703489752865,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"Can give more incentive back&nbsp;to users for using VisaLike and comments pls. Thanks.&nbsp;","listText":"Can give more incentive back&nbsp;to users for using VisaLike and comments pls. Thanks.&nbsp;","text":"Can give more incentive back to users for using VisaLike and comments pls. Thanks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/803884988","repostId":"2154894857","repostType":4,"repost":{"id":"2154894857","pubTimestamp":1627430042,"share":"https://ttm.financial/m/news/2154894857?lang=&edition=fundamental","pubTime":"2021-07-28 07:54","market":"us","language":"en","title":"Visa gets vaccine boost as domestic spending back near pre-COVID levels","url":"https://stock-news.laohu8.com/highlight/detail?id=2154894857","media":"Reuters","summary":"July 27 (Reuters) - Visa Inc beat estimates for quarterly profit on Tuesday, with domestic spending ","content":"<p>July 27 (Reuters) - <a href=\"https://laohu8.com/S/V\">Visa</a> Inc beat estimates for quarterly profit on Tuesday, with domestic spending almost back to pre-pandemic levels and international travel on the road to recovery as rising vaccinations and reopening economies take effect.</p>\n<p>Payment companies are seeing an uptick in volumes from the coronavirus-induced slump as travel and entertainment spending gathers force, while the rise of e-commerce during lockdowns also drives transactions.</p>\n<p>Visa reported a 34% jump in third-quarter payment volumes on a constant dollar basis, while the number of transactions processed surged 39%.</p>\n<p>\"In our domestic businesses, we are pretty much back to where we were, had the pandemic never happened,\" Chief Financial Officer Vasant Prabhu told Reuters.</p>\n<p>\"The <a href=\"https://laohu8.com/S/AONE.U\">one</a> area of our business that is still not back to where it was is cross-border travel. That is the next stage of recovery,\" he said.</p>\n<p>Cross-border volumes jumped 47% on a constant currency basis in the quarter.</p>\n<p>Travel spending volumes at Visa were approaching 2019 levels in July, while entertainment surpassed those levels in May, Prabhu told analysts on a call.</p>\n<p>Total revenue climbed 27% to $6.13 billion. Assuming July trends continue, Visa's fourth-quarter net revenue growth is expected to be in line with the third quarter, Prabhu said.</p>\n<p>Net income rose to $2.58 billion in the quarter ended June 30 from $2.37 billion a year earlier. On an adjusted basis, Visa reported a profit of $1.49 per share, compared with Refinitiv estimates of $1.35.</p>\n<p>Prabhu said there was no evidence of an impact from the Delta variant of the coronavirus on people buying things in their home countries.</p>\n<p>\"Even as infections are climbing, people don't seem to be changing their habits like they were before,\" he said.</p>\n<p>A recent announcement by the UK and Canada regarding border openings in August should boost the current quarter, Prabhu added. (Reporting by Noor Zainab Hussain in Bengaluru; Editing by Devika Syamnath and Shinjini Ganguli)</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Visa gets vaccine boost as domestic spending back near pre-COVID levels</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVisa gets vaccine boost as domestic spending back near pre-COVID levels\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-28 07:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-visa-profit-jumps-vaccinations-205102095.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 27 (Reuters) - Visa Inc beat estimates for quarterly profit on Tuesday, with domestic spending almost back to pre-pandemic levels and international travel on the road to recovery as rising ...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-visa-profit-jumps-vaccinations-205102095.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"V":"Visa"},"source_url":"https://finance.yahoo.com/news/1-visa-profit-jumps-vaccinations-205102095.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2154894857","content_text":"July 27 (Reuters) - Visa Inc beat estimates for quarterly profit on Tuesday, with domestic spending almost back to pre-pandemic levels and international travel on the road to recovery as rising vaccinations and reopening economies take effect.\nPayment companies are seeing an uptick in volumes from the coronavirus-induced slump as travel and entertainment spending gathers force, while the rise of e-commerce during lockdowns also drives transactions.\nVisa reported a 34% jump in third-quarter payment volumes on a constant dollar basis, while the number of transactions processed surged 39%.\n\"In our domestic businesses, we are pretty much back to where we were, had the pandemic never happened,\" Chief Financial Officer Vasant Prabhu told Reuters.\n\"The one area of our business that is still not back to where it was is cross-border travel. That is the next stage of recovery,\" he said.\nCross-border volumes jumped 47% on a constant currency basis in the quarter.\nTravel spending volumes at Visa were approaching 2019 levels in July, while entertainment surpassed those levels in May, Prabhu told analysts on a call.\nTotal revenue climbed 27% to $6.13 billion. Assuming July trends continue, Visa's fourth-quarter net revenue growth is expected to be in line with the third quarter, Prabhu said.\nNet income rose to $2.58 billion in the quarter ended June 30 from $2.37 billion a year earlier. On an adjusted basis, Visa reported a profit of $1.49 per share, compared with Refinitiv estimates of $1.35.\nPrabhu said there was no evidence of an impact from the Delta variant of the coronavirus on people buying things in their home countries.\n\"Even as infections are climbing, people don't seem to be changing their habits like they were before,\" he said.\nA recent announcement by the UK and Canada regarding border openings in August should boost the current quarter, Prabhu added. (Reporting by Noor Zainab Hussain in Bengaluru; Editing by Devika Syamnath and Shinjini Ganguli)","news_type":1},"isVote":1,"tweetType":1,"viewCount":224,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172765534,"gmtCreate":1626995289028,"gmtModify":1703481910951,"author":{"id":"3586303845668227","authorId":"3586303845668227","name":"StayHome","avatar":"https://static.tigerbbs.com/a2090cc80fca211990d8fc4e216f75b7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586303845668227","authorIdStr":"3586303845668227"},"themes":[],"htmlText":"Inflation has cause&nbsp;things to become more expensive, therefore ppl also demand more wages ….","listText":"Inflation has cause&nbsp;things to become more expensive, therefore ppl also demand more wages ….","text":"Inflation has cause things to become more expensive, therefore ppl also demand more wages ….","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172765534","repostId":"1172546594","repostType":4,"repost":{"id":"1172546594","pubTimestamp":1626963813,"share":"https://ttm.financial/m/news/1172546594?lang=&edition=fundamental","pubTime":"2021-07-22 22:23","market":"us","language":"en","title":"Biden Downplays Inflation, Predicts Businesses Will Be In 'Bind' Over Labor Shortages, Then Has Brain Freeze","url":"https://stock-news.laohu8.com/highlight/detail?id=1172546594","media":"zerohedge","summary":"President Joe Biden waved off long-term inflation concerns on Wednesday, telling aCNNtown hall in Ci","content":"<p>President Joe Biden waved off long-term inflation concerns on Wednesday, telling a<i>CNN</i>town hall in Cincinnati that it won't persist as the economy emerges from the pandemic.</p>\n<p><img src=\"https://static.tigerbbs.com/667604940c5d09d04d8141c6810c2609\" tg-width=\"500\" tg-height=\"304\" width=\"100%\" height=\"auto\"></p>\n<p>\"<b>There will be near-term inflation</b>\" because the economy is recovering, he said, adding that 'most economists' think \"it’s highly unlikely that it’s going to be long-term inflation that’s going to get out of hand.\"</p>\n<p><img src=\"https://static.tigerbbs.com/1a683ce14e2b21dab4dac41ad2dcd5ac\" tg-width=\"513\" tg-height=\"507\" width=\"100%\" height=\"auto\">He then cautioned restaurant owners and others in the hospitality sector that recovery may not be swift - telling one restaurant owner that he may be \"in a bind for a while\" because workers are seeking better wages and working conditions, according to<i>Bloomberg</i>.</p>\n<p><b>\"It really is a matter of people deciding now that they have opportunities to do other things</b>,\" he said, adding \"People are looking to make more money and to bargain.\"</p>\n<blockquote>\n <i>Inflation has become a political liability for the White House in recent weeks. The U.S. experienced the largest surge in consumer prices in more than 12 years last month, with a Labor Department gauge rising 5.4% compared to one year ago.</i>\n</blockquote>\n<blockquote>\n <i>“</i>\n <i><b>Inflation is driving the cost of everything through the roof</b></i>\n <i>,” Senate Minority Leader Mitch McConnell of Kentucky said at a news conference Wednesday opposing Democratic calls for Biden’s long-term social spending plan. -Bloomberg</i>\n</blockquote>\n<p>Republicans, meanwhile, largely blame Biden and Democrats for the labor shortages at restaurants and other low-wage businesses<b>because overly-generous pandemic stimulus has removed incentives to get back to work</b>. Biden, in response, suggests these low-margin businesses should simply pay people more - calling rising wages a \"feature' of his economic plans.</p>\n<p><img src=\"https://static.tigerbbs.com/6dd04b1d760874109565cfabae2d919e\" tg-width=\"971\" tg-height=\"559\" width=\"100%\" height=\"auto\"></p>\n<p><b>J</b><b>ob openings continue to hit record highs</b>despite elevated unemployment. According to the report, the hotel and restaurant industries had 1.25 million vacant jobs in May, up from 807,000 in February 2020.</p>\n<p>\"A lot of people who work as waiters and waitresses decided that they don’t want to do that anymore because there’s other opportunities and higher wages, because there’s a lot of openings now and jobs and people are beginning to move,\" said Biden.</p>\n<p><b>Infrastructure, Vaccinations</b></p>\n<p>Biden also expressed confidence that he can still secure the passage of a $1 trillion bipartisan infrastructure package despite GOP lawmakers blocking its first congressional vote on Wednesday - which Biden called \"irrelevant.\"</p>\n<p>\"It’s necessary, I really mean it. It’s going to not only increase job opportunities but increase commerce. It’s a good thing and I think we’re going to get it done,\" he said.</p>\n<p>As the<i>Financial Times</i>notes, \"Although US growth and job creation have jumped since Biden took office in January,<b>the economic outlook has been clouded by the resurgence of coronavirus because of the rapid spread of the contagious Delta variant as well as an unnerving rise in inflation</b>.\"</p>\n<p>Biden also pushed vaccinations, which have slowed in the United States as cases nudge higher. He said they would receive final approval from the Food and Drug Administration soon, and would be available for children under the age of 12.</p>\n<p>\"We have a pandemic for those who haven’t gotten the vaccination. It’s that basic, that simple,\" he said. \"<u><i><b>If you’re vaccinated, you’re not going to be hospitalized</b></i></u>.<i><b>You’re not going to be in an ICU unit. And you are not going to die.</b></i>\"</p>\n<p><b>Except40% of UK hospital admissionsare those who have been vaccinated, while Israel has had even higher numbers</b>, and the most vaccinated countries are experiencing<b>COVID case spikes</b>vs. the least-vaccinated. Meanwhile, over 6,000 people have<i>officially</i>died shortly after receiving the vaccine, according to the&nbsp;CDC.</p>\n<p><img src=\"https://static.tigerbbs.com/174a8c547f5a0be8e7a4018d1d646579\" tg-width=\"916\" tg-height=\"478\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/17e0835984a9d20a1a321432753ad11f\" tg-width=\"521\" tg-height=\"334\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/0d35eded3a3bfac23a186cb7feee6a80\" tg-width=\"516\" tg-height=\"648\" width=\"100%\" height=\"auto\">Biden had an<b>awkward brain freeze</b>during the vaccine Q&amp;A.</p>\n<p><img src=\"https://static.tigerbbs.com/106e46a3028532086fc49841235f2fd1\" tg-width=\"510\" tg-height=\"460\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/83ce29d43f252b5b72c5106e5d5f3652\" tg-width=\"518\" tg-height=\"552\" width=\"100%\" height=\"auto\"></p>\n<p><b>Filibuster</b></p>\n<p>Biden slammed Republican legislators over voting integrity legislation, calling them \"Jim Crow on steroids,\" however<b>he maintained his support for the legislative filibuster</b>.</p>\n<p>\"There’s no reason to protect it other than you’re going to throw the entire Congress into chaos and nothing will get done,\" adding \"Nothing at all will get done.\" He followed up by saying that there was 'too much at stake' to risk that level of 'chaos' that a filibuster fight would ignite.</p>\n<p><img src=\"https://static.tigerbbs.com/76d8c272e874c5a6f1934e8124015d02\" tg-width=\"516\" tg-height=\"641\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biden Downplays Inflation, Predicts Businesses Will Be In 'Bind' Over Labor Shortages, Then Has Brain Freeze</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiden Downplays Inflation, Predicts Businesses Will Be In 'Bind' Over Labor Shortages, Then Has Brain Freeze\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 22:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/political/biden-downplays-inflation-predicts-businesses-will-be-bind-over-persistent-labor><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>President Joe Biden waved off long-term inflation concerns on Wednesday, telling aCNNtown hall in Cincinnati that it won't persist as the economy emerges from the pandemic.\n\n\"There will be near-term ...</p>\n\n<a href=\"https://www.zerohedge.com/political/biden-downplays-inflation-predicts-businesses-will-be-bind-over-persistent-labor\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite","SPY":"标普500ETF",".SPX":"S&P 500 Index"},"source_url":"https://www.zerohedge.com/political/biden-downplays-inflation-predicts-businesses-will-be-bind-over-persistent-labor","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172546594","content_text":"President Joe Biden waved off long-term inflation concerns on Wednesday, telling aCNNtown hall in Cincinnati that it won't persist as the economy emerges from the pandemic.\n\n\"There will be near-term inflation\" because the economy is recovering, he said, adding that 'most economists' think \"it’s highly unlikely that it’s going to be long-term inflation that’s going to get out of hand.\"\nHe then cautioned restaurant owners and others in the hospitality sector that recovery may not be swift - telling one restaurant owner that he may be \"in a bind for a while\" because workers are seeking better wages and working conditions, according toBloomberg.\n\"It really is a matter of people deciding now that they have opportunities to do other things,\" he said, adding \"People are looking to make more money and to bargain.\"\n\nInflation has become a political liability for the White House in recent weeks. The U.S. experienced the largest surge in consumer prices in more than 12 years last month, with a Labor Department gauge rising 5.4% compared to one year ago.\n\n\n“\nInflation is driving the cost of everything through the roof\n,” Senate Minority Leader Mitch McConnell of Kentucky said at a news conference Wednesday opposing Democratic calls for Biden’s long-term social spending plan. -Bloomberg\n\nRepublicans, meanwhile, largely blame Biden and Democrats for the labor shortages at restaurants and other low-wage businessesbecause overly-generous pandemic stimulus has removed incentives to get back to work. Biden, in response, suggests these low-margin businesses should simply pay people more - calling rising wages a \"feature' of his economic plans.\n\nJob openings continue to hit record highsdespite elevated unemployment. According to the report, the hotel and restaurant industries had 1.25 million vacant jobs in May, up from 807,000 in February 2020.\n\"A lot of people who work as waiters and waitresses decided that they don’t want to do that anymore because there’s other opportunities and higher wages, because there’s a lot of openings now and jobs and people are beginning to move,\" said Biden.\nInfrastructure, Vaccinations\nBiden also expressed confidence that he can still secure the passage of a $1 trillion bipartisan infrastructure package despite GOP lawmakers blocking its first congressional vote on Wednesday - which Biden called \"irrelevant.\"\n\"It’s necessary, I really mean it. It’s going to not only increase job opportunities but increase commerce. It’s a good thing and I think we’re going to get it done,\" he said.\nAs theFinancial Timesnotes, \"Although US growth and job creation have jumped since Biden took office in January,the economic outlook has been clouded by the resurgence of coronavirus because of the rapid spread of the contagious Delta variant as well as an unnerving rise in inflation.\"\nBiden also pushed vaccinations, which have slowed in the United States as cases nudge higher. He said they would receive final approval from the Food and Drug Administration soon, and would be available for children under the age of 12.\n\"We have a pandemic for those who haven’t gotten the vaccination. It’s that basic, that simple,\" he said. \"If you’re vaccinated, you’re not going to be hospitalized.You’re not going to be in an ICU unit. And you are not going to die.\"\nExcept40% of UK hospital admissionsare those who have been vaccinated, while Israel has had even higher numbers, and the most vaccinated countries are experiencingCOVID case spikesvs. the least-vaccinated. Meanwhile, over 6,000 people haveofficiallydied shortly after receiving the vaccine, according to the CDC.\nBiden had anawkward brain freezeduring the vaccine Q&A.\n\nFilibuster\nBiden slammed Republican legislators over voting integrity legislation, calling them \"Jim Crow on steroids,\" howeverhe maintained his support for the legislative filibuster.\n\"There’s no reason to protect it other than you’re going to throw the entire Congress into chaos and nothing will get done,\" adding \"Nothing at all will get done.\" He followed up by saying that there was 'too much at stake' to risk that level of 'chaos' that a filibuster fight would ignite.","news_type":1},"isVote":1,"tweetType":1,"viewCount":60,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}